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Abstract: Diabetes mellitus, a disease of modern civilization, is considered the major mainstay
of mortalities around the globe. A great number of biochemical changes have been proposed to
occur at metabolic levels between perturbed glucose, amino acid, and lipid metabolism to finally
diagnoe diabetes mellitus. This window period, which varies from person to person, provides us
with a unique opportunity for early detection, delaying, deferral and even prevention of diabetes.
The early detection of hyperglycemia and dyslipidemia is based upon the detection and identification
of biomarkers originating from perturbed glucose, amino acid, and lipid metabolism. The emerging
“OMICS” technologies, such as metabolomics coupled with statistical and bioinformatics tools, proved
to be quite useful to study changes in physiological and biochemical processes at the metabolic level
prior to an eventual diagnosis of DM. Approximately 300–400 such metabolites have been reported
in the literature and are considered as predicting or risk factor-reporting metabolic biomarkers for
this metabolic disorder. Most of these metabolites belong to major classes of lipids, amino acids
and glucose. Therefore, this review represents a snapshot of these perturbed plasma/serum/urinary
metabolic biomarkers showing a significant correlation with the future onset of diabetes and providing
a foundation for novel early diagnosis and monitoring the progress of metabolic syndrome at early
symptomatic stages. As most metabolites also find their origin from gut microflora, metabolism and
composition of gut microflora also vary between healthy and diabetic persons, so we also summarize
the early changes in the gut microbiome which can be used for the early diagnosis of diabetes.
Keywords: metabolomics; validated biomarkers; early biomarkers; diabetes mellitus; pre-diabetes;
glucose intolerance; insulin resistance; obesity; gut microbiota
1. Introduction
Diabetes mellitus (DM) is the most prevalent modern civilization disease and 8th major mainstay
of mortalities globally. This worldwide pandemic of DM is associated with large financial strain on the
healthcare systems of many countries, especially developing ones. The current projections from the
International Diabetic Federations (IDF) predict that the number of diabetic patients will hit 629 million
by 2045 and 34 million more people are at risk of developing DM than in 2015. Approximately 19 million
more adult people are undiagnosed than in 2015 and 1 in 6 births are influenced by hyperglycemia
in pregnancies [1]. Governments have allocated and spent almost USD 792 billion worldwide for
the treatments of DM, out which almost 377 and 166 billion dollars were allocated and spent only by
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the US and European Union (EU) countries. In the developing countries the financial burden of DM
treatment is mostly beard by patients themselves and it accounts for 25–40% of their monthly income.
However, to make matters worse, 4 out of 5 people with diabetes live in low- and middle-income
countries [1,2]. Therefore, new approaches are needed to lessen this financial pressure on both patients
and healthcare systems which is achievable only by reducing the epidemic of DM.
To circumvent the onset and/or delay in the progress of DM, it is most effective to recognize the
early stages of DM before major systematic damage (i.e., retinopathy, microvascular complications,
nephropathy etc.) occurs. Currently, a number of laboratory-based-diagnostic-tools are available
for the early detection of metabolic syndrome and related diseases which include impaired glucose
tolerance (IGT), impaired fasting glucose (IFG), combined glucose tolerance (CGT) tests, anthropometric
measurements and insulin sensitivity indexes [3]. These laboratory-based-tests are related to the
(pre)diabetic state which may take years to proceed to chronic DM. The aforementioned diagnostic
tests are directly related to glucose and insulin homeostasis. However, non-glucose/insulin related
reliable and validated biomarkers are needed to complement our knowledge on diabetes development
and indicate prognostic biomarkers. Regarding this, it has also been reported in the literature that
metabolic syndrome (pre-diabetic/diabetic state) is likely to alter the metabolic pathways related
to sugars, lipids, amino acids and their resulting metabolites resulting in the perturbed respective
metabolites level in predisposed individuals compared to healthy ones [4]. These altered metabolite
levels may serve as non-glucose/non-insulin related reliable and validated diagnostic biomarkers to
recognize the pre-diabetic stage. Furthermore, many beneficial metabolites are produced as a result of
intestinal microflora’s metabolism on sugars, lipids and amino acids. Therefore, metagenomic studies
of gut microbiota have also been considered complementary to metabolomics studies to summarize
the reported changes in the gut microbiota ecosystem.
A high throughput analytical technique such as metabolomics is immensely popular in
epidemiological studies to provide the mining of these new reported biomarkers of disease risks
and severity. This approach has the capability to detect the perturbation of one’s body metabolic
pathways affected by disease and hence permit new insights into the physiological and pathophysiological
development of disease [5]. The metabolomics technique has been used for screening potential diabetic
patients for early diagnosis, prevention or delayed onset of type 2 diabetes mellitus (T2DM). Literature
is full of many prospective, randomized, blinded, nested and case-controlled cohort studies where
the populations of different geographical localities have been recruited and tested for decades to
comprehensively understand the prognosis of DM in both vulnerable and non-vulnerable subjects.
These studies came up with a wide range of early T2DM biomarkers, especially of sugars, lipids and
amino acids origin. Most of these (pre)diabetes reporting biomarkers originating from sugars, lipids and
amino acids metabolism are considered validated biomarkers. However, a few conflicting studies are also
presented in literature and discussed in this review too. Most of these conflicts in findings may arise due
to not considering varying covariates in research design and personal or communal genetic variations.
The data regarding the early biomarkers of DM (T2DM) in human beings is really dispersed
and exhaustive. Therefore, the objectives of this comprehensive review were, for the first time in
literature, to collect, compile and update as much reliable and validated early DM biomarkers data in
one manuscript from published literature, which will be convenient for both physicians and potential
DM sufferers to score their risk factors.
2. Metabolomics and Early Biomarker of Type 2 Diabetes Mellitus (T2DM)
The global prevalence of the T2DM pandemic has attracted wide attention due to its
financial burden on health care systems. The failure in diagnosing prediabetes by conservative
laboratory-based diagnosis tools at their latest stages could also be partially blamed for this pandemic.
The laboratory-based diabetes diagnostic tools which are currently available include fasting blood
glucose levels, insulin sensitivity indexes, oral glucose tolerance tests (OGTT) and glycated hemoglobin
(HbA1c). It is estimated that up to 60% of cases of T2DM have never been diagnosed and/or misdiagnosed
due to the sensitivity limitations of these assays at prediabetic and diabetic threshold levels [6].
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Additionally, these trivial assays are not involved in staging the progress of diabetes as T2DM
is considered a non-static condition and it keeps evolving from acute prediabetic (hypoglycemia,
hyperosmolar hyperglycemic syndrome, ketoacidosis, and lactic acidosis) to chronic diabetic (diabetic
coronary artery disease (CAD), cerebral vascular disease, diabetic retinopathy (DR), diabetic peripheral
neuropathy, lower extremity vascular disease, diabetic nephropathy (DN) and diabetic foot disease)
states [7]. The misdiagnosis and mistreatment of prediabetes and prediabetic complications has not
only exposed people to non-essential medications with possible side effects but also to a source of
economic loss. Preventing the onset of T2DM and/or diagnosing the early stages of diabetes followed
by respective targeted treatment is the most economical way to treat T2DM before the occurrence of
systematic damage and chronic complications. Apparently, the failure of the diabetic diagnostic tools
currently available to diagnose prediabetes makes the search inevitable for new biomarkers/predictors
to complement the current diagnostic measures. Recently, the inclusion of low plasma adiponectin
concentration as a strong predictor for future T2DM development [8] further suggests the significant
scope of setting the complementary biomarkers of T2DM risk. Moreover, highly sensitive and specific
biomarkers are urgently needed in order to early diagnose T2DM. Metabolomics provides a great
opportunity to indicate these novel biomarkers.
Metabolomics has been increasingly used in epidemiological studies for unveiling the novel
association between metabolic pathways and disease. It is referred to a systematic study of identification
and quantification of low molecular-weight metabolites in a given biological sample. The pool of
these metabolites plays an important physiological role in the biological systems and is considered a
promising candidate for studying disease phenotype as disrupted levels of metabolites were found
in prediabetic individuals [9]. Two major platforms are used in metabolomics research, i.e., mass
spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. MS, the most frequently
employed approach, is high-throughput and sensitive but destructive in nature. It is often used in
combination with separation techniques such as (high/ultra-pressure) liquid chromatography, gas
chromatography and capillary electrophoresis. NMR, on the other hand, is non-destructive, robust and
reproducible with minimal sample preparation, separation and ionization steps. As no single platform
exists to capture the global profile of the whole metabolome, a multiplatform approach is mostly applied
to get an all-inclusive understanding of metabolic variations and widen the “window” of significant
metabolic discrepancies [10]. The application of metabolomics in T2DM studies has been in progress
for the last two decades with the successful provision of novel insights into the pathophysiological
mechanism and metabolic profiling. These studies have come up with the identification of novel
biomarkers related to insulin resistance and T2DM biomarkers [3,4,10]. It is highly probable that a
growing number of these novel T2DM biomarkers can be translated into clinical applications that will
upgrade the current medical routine in regards to personalized medicine.
3. Biomarkers of Disturbed Protein Metabolism
Protein and glucose metabolism are tightly linked and accordingly regulated at metabolic
and molecular levels. Dietary and endogenous amino acids (AA) relate to glucose metabolism via
gluconeogenesis. The catabolic breakdown of AA provides the fuel for gluconeogenesis. The deamination
of AA forms ketoacids such as oxaloacetate and pyruvate which feed the gluconeogenesis [11,12]. On
the other hand, AA are also de novo biosynthesized from the Krebs cycle-derived carboxylic
acid-intermediates by transamination. These free AA modulate the AA-type-dependent glucagon
and insulin secretion and hence glucose metabolism [13]. In short, AA are not only an energy reservoir
for gluconeogenesis, but their de novo biosynthesiz influences the glucagon and insulin release. In
prediabetes, the glucagon not only over-activates the gluconeogenesis in the liver and kidneys but also
disrupts the de novo biosynthesis of AA, which makes the AA good candidate biomarkers. In the
meantime, many studies have claimed a positive association of branched-chained AA (BCAA), aromatic
AA and other AA with the risk of developing T2DM as follows.
AA: Elevated (serum/plasma) AA level is an important early biomarker of glucose intolerance,
insulin insensitivity and, subsequently, diabetes. Many epidemiological cohort studies have witnessed
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an increased level of AA in newly diagnosed diabetic patients in the follow up investigations hinting
towards an impaired glucose/hexoses metabolism [14]. An increased serum AA level reduced the
insulin sensitivity and uptake of hexoses by offering competition at the substrate level to glucose
oxidation and also by interfering with insulin signaling [11,13]. Higher serum AA levels were found
to diminish the peripheral uptake of hexoses along with the suppression of endogenous glucose
production (EGP) and body glucose disposal by 25% [15]. Similarly, the rate of glycogen synthesis was
recorded to reduce up to 64% with a rise in serum AA levels under insulin stimulated conditions which
accounted for AA modulated reduced glucose absorption in the body. This decline in glucose absorption
is accompanied by the down-regulation of glycogen synthase, glucose transporter, phosphorylations
and G6P [11,16]. Many studies have recorded this increased AA level as a future risk factor of
developing T2DM. Most of these AA not only belong to BCAA but also to aromatic and aliphatic AA.
In a closely matched case-control study, three aromatic (phenylalanine, tyrosine, and tryptophan) and
one aliphatic AA (lysine) were found to be associated with the future risk of T2DM. The predictive
power of lysine was also viable after the OGTT while comparing cases vs. controls. The additional
stratified analysis in follow-up duration recorded the retainability of the predictive power of these AA
up to 12 years from the baseline. For each increase in the SD of these AA, the odds of future T2DM
development increased by 57–102%, further signaling towards a 2- to 3.5-fold higher probability of
developing T2DM in top quartile individuals. The conditional regression analysis with isoleucine,
phenylalanine and tyrosine also reported a five- to seven-fold higher probability of developing T2DM
in top quartile individuals [17]. In the Insulin Resistance Atherosclerosis (IRAS) cohort, the individuals
of four ethnicities (European-American, Hispanic, and African-American) who converted to T2DM
in their follow-up of five years recorded similar results. A distinctive metabolome profile was noted
in T2DM-converted subjects compared to healthy controls with significantly higher concentrations
of phenylalanine, tyrosine, combined glutamine and glutamate, and valine associated with insulin
resistance (Table 1). An 11–15% increase in these AA was seen whereas a 22% lower level of glycine was
noted in highly insulin resistant individuals. A nominal difference was also noted between high/low
insulin-resistant persons to T2DM-convertees. Alanine and aspartate/asparagine levels increased in
the T2DM-converters only compared to high/low insulin resistant persons [18]. The SABRE (Southall
and Brent Revisited) cohort study comprised of non-diabetic South Asian migrants in Europe/UK
pinpointed nine AA in relation with the biomarker of obesity and insulin resistance in a follow up of
19 years. This study also described a significant positive correlation of phenylalanine, tyrosine and
alanine, a weak positive relationship of histidine, and a significant negative correlation of glutamine
and glycine with insulin resistance and glycemia [19]. In another Asian-Japanese cohort study, the
authors measured the level of plasma-free AA (BCAA and aromatic AA) in correlation with obesity
and diabetes and was able to predict the future diabetes risk in a minimal time of four years. This study
further cited the negative correlation of clusters of glycine, serine, glutamine, and asparagine with
obesity, body mass index (BMI), insulin resistance and 120 min insulin resistance assay. The increment
of 1 SD of the odds ratios of the plasma-free AA increased the future risk of T2DM, metabolic syndrome,
dyslipidemia or hypertension by 2.06%, 3.04%, 1.98%, and 1.42% respectively [20]. The longitudinal,
nested and cross-sectional studies from two Chinese cohorts, Shanghai Obesity Study (SHOS) and
Shanghai Diabetes Study (SHDS), also noted increased serum levels of aromatic AA at baseline in
those individuals who develop T2DM in a follow up of 10 years [21]. The Finnish cohort study of 9369
nondiabetic or newly diagnosed T2DM Finnish men, namely population-based Metabolic Syndrome
in Men (METSIM) also cited increased concentrations of tyrosine, glutamine and alanine in a 4.7-year
follow-up [22]. An aliphatic AA called 2-aminoadipic acid was also found to be an early biomarker for
T2DM risk. The degradation of lysine usually results in the 2-aminoadipic acid that may serve as a
substrate for tryptophan catabolism. A strong association of 2-aminoadipic acid with T2DM risk was for
the first time cited by Wang et al. [23]. The fasting plasma levels of prediabetic patients were found to be
high in this amino acid. Following adjustments for age, sex, BMI and fasting conditions, the conditional
logistics regression models noted 60% odds of future T2DM risk after each standard deviation (SD)
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increment of a logged biomarker. The twelve years-follow up-period showed 4-fold higher odds of
developing T2DM in the top quartiles of plasma 2-aminoadipic acid concentration. The adjustment
of data with respect to parental history, dietary habits, lifestyle, fat/protein/carbohydrate intake and
total caloric intake did not bring about any variations in this risk factor [24,25]. The independent
work on Malmo diets and cancer studies also served as a replication of these results, which also
indicated a 57% rise in the T2DM risk for each increment of SD of 2-aminoadipic acid concentration.
Aromatic and branched-chain amino acids are also biomarkers of incidence of T2DM, but recent
studies have not found any correlation between 2-aminoadipic acid and aromatic or branched-chain
amino acids. However, a modest association of 2-aminoadipic acid with lysine, kynurenic acid and
anthranilic acid was observed [16,23]. The Dongfeng–Tongji (DFTJ) and Jiangsu non-communicable
disease (JSNCD) independent nested case control cohort models were also used to predict the identified
metabolites using the traditional risk factors [26]. Qiu et al. [26] identified 52 metabolites, among
which 20 AA were found to have associated positively with DM risk in both models. The dietary
variables also did not change the four AA biomarkers out of 20 (i.e., alanine, phenylalanine, tyrosine
and palmitoylcarnitine) which had a false discovery rate correction (FDR) < 0.01. The exploratory
analysis of the pooling of other metabolites also identified an additional 12 metabolites, including
such AA as glutamate, betaine, ornithine, leucine/isoleucine, valine and proline which achieved
FDR < 0.01. The four metabolites i.e., phenylalanine, alanine, palmitoylcarnitine and tyrosine were
found consistently associated with the risk of T2DM. Another aliphatic AA called alanine is a hepatic
substrate and stimulator for gluconeogenesis and glucagon secretion and its circulating amount
was also found to be a predictive metabolite of T2DM risk in many cross-sectional and prospective
studies [4,27]. Elevated levels of alanine have already been found to have a positive association with
T2DM in Finland, UK, and South Asia populations, as stated above. Moreover, the evident relationship
of phenylalanine and tyrosine with the risk of T2DM was also significant due to an increase in insulin
resistance through blocking the transport/phosphorylation of glucose. In the case of tyrosine, it is a far
more powerful indicator of T2DM risk in South Asians [27]. The population-based KORA (Cooperative
Health Research in the Region of Augsburg) and European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam cohort study identified five baseline metabolites out of 131 (using pairwise
comparison, multivariate (logistic) regression analyses followed by non-parametric random forest
and the stepwise parametric regression) specifically associated with the pre-diabetic conditions to
examine their ability to forecast the pre-diabetic conditions earlier [4]. The non-parametric random
forest and the stepwise parametric regression recorded glycine, (lysophosphatidylcholines (LysoPC)
(18:2), LysoPC (17:0), LysoPC (18:1) and C2) as novel candidate biomarkers of T2DM. In pursuit of
establishing the predictive values of these metabolites, the baseline concentration of these metabolites
in the KORA cohort (118 incident and 471 healthy controls) were compared, which revealed significant
differences only for glycine and LysoPC (18:2). Each increment in the standard deviation of these two
metabolites associated with a 33% less risk of future diabetes. The individuals in the fourth quartile
were at three times less risk of diabetes than people whose serum glycine and LysoPC (18:2) levels
were at first quartile. Therefore, the baseline decreases in the serum levels of glycine and LysoPC
(18:2) were cited as powerful indicators of the future onset of diabetes [4]. Later on, the replicative
prospective study with EPIC-Potsdam cohort also reported similar results using targeted metabolomics
citing an increased phenylalanine concentration and reduced glycine concentration as biomarkers for
future T2DM occurrence [28]. Earlier, the work of Pontiroli et al. [29] also confirmed a low level of
glycine as a result of progressive insulin resistance which, in turn represses, the expression of ALAS-H
catalyzing the conversion of glycine and succinyl-CoA into 5-aminolevulinic acid. In short, most of the
early diabetes biomarker mining studies find AA as early predictors of T2DM. In summary, with the
exceptions of glycine, serine, asparagine and histidine, most of studies stated increased concentrations
of AA as a risk predictor of the future onset of T2DM. The predicting power of different AA may vary
depending on the early diabetic stage, ethnicities and genetic background.
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Table 1. A comprehensive list of altered metabolites of lipids and amino acid (AA) origins found in cohort studies mentioned in the respective sections.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
1
Branched-chain-amino
acids/Amino acids
(BCAA/AA)
N-Acetylaspartate ↓ plasma/urine Alanine and aspartate metabolism
2 Phosphocreatine ↑ plasma/urine Creatine biosynthesis and amino acid
3 Creatinine ↑ plasma/urine Metabolism, glycine, serine and threonine
4 Glycine ↓ plasma/urine Metabolism
5 Guanidinoacetate ↑ plasma/urine AA metabolism
6 Butyrylglycine ↓ plasma/urine FA metabolism
7 Caproylglycine ↓ plasma/urine Fatty acid metabolism
8 N-Acetylglutamate ↑ plasma/urine Glutamate pathway (link with urea cycle)
9 Choline ↑ plasma/urine Glycine, serine and threonine metabolism
10 Threonine ↑ plasma/urine AA metabolism
11 Valerylglycine ↓ plasma/urine AA metabolism
12 Alanine ↑ plasma/urine Glycolysis, alanine and aspartatemetabolism
13 2-Oxoadipate ↑ plasma/urine Lysine degradation
14 Lysine ↑ plasma/urine biosynthesis
15 Glutaric acid ↓ plasma/urine Lysine degradation, fatty acid metabolism
16 Methionine ↑ plasma/urine Methionine metabolism
17 Taurine ↑ plasma/urine Taurine and hypotaurine metabolism
18 Tyrosine ↑ plasma/urine Tryptophan metabolism
19 Indoxyl sulfate ↓ plasma/serum Tyrosine metabolism
20 Citrulline ↑ plasma/serum
Urea cycle21 l-Argininosuccinic acid ↑ plasma/serum
22 N-Acetyl citrulline ↑ plasma/serum
23 Ornithine ↑ plasma/serum
24 Isobutyrlglycine ↓ plasma/serum
val, leu and ileu degradation
25 Isovalerate ↓ plasma/serum
26 Isovalerylglycine ↓ plasma/serum
27 Methylmalonate ↓ plasma/serum
28 Valine ↑ plasma/serum
J. Clin. Med. 2020, 9, 2257 7 of 46
Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
29 Glutamylvaline ↑ plasma/serum dipeptide metabolism
30 Gamma-glutamylisoleucine ↑ plasma/serum g-glutamyl metabolism
31 3-hydroxybutyrate (BHB) ↑ plasma/serum ketone bodies degradation
32 Phenylacetylglutamine ↑ plasma/serum Phenylalanine and tyrosine degradation
33 Phenylalanine ↑ plasma/serum Phenylalanine and tyrosine degradation
34 Homocitrulline ↑ plasma/serum Urea cycle
35 Phenylacetylglutamine ↑ plasma/serum Dipeptide
36 Glutamylvaline ↑ plasma/serum Saturated fatty acids
37 Gamma-glutamylisoleucine ↑ plasma/serum g-glutamyl metabolism
38 N-acetylalanine ↑ plasma/serum BCAA metabolism
39 Cysteine ↓ plasma/serum Amino-sugars metabolism
40 Leucine ↑ plasma/serum AA metabolism
41 2-ketoisocaproic acid and 2-hydroxybutanoic ↑ plasma/serum Leucine and methionine metabolism
42 cystine ↑ plasma/serum AA metabolism
43 Histidine ↑ plasma/serum AA metabolism
44 Lysine/serine/aspergine ↓ plasma/serum AA metabolism
45 5-l-Glutamyl-taurine ↑ Urine AA metabolism
46 4-Oxoproline ↑ Urine AA metabolism
47 l-Valine ↑ Urine AA metabolism
48 N-formylproline ↑ Urine AA metabolism
49 N-(3-hydroxybenzoyl)glycine ↑ Urine AA metabolism
50 3-Hydroxyphenylacetic acid ↑ Urine AA metabolism
51 Glucuronide compound ↑ Urine AAmetabolism
52 d-Glutamicacid ↑ Urine Amino acids metabolism
53 Glutamine ↓ plasma/serum Amino acids metabolism
54 2-aminoadipic acid ↑ plasma/serum Tryptophan metabolism
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Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
55
(Acyl)carnitines
Total carnitine ↑ plasma/serum
Mitochondrial fatty acids metabolism
56 Free Carnitine ↑ plasma/serum
57 Acetylcarnitine (C2) ↓ plasma
58 Propionylcarnitine (C3), C14:2 and C18 acylcarnitines ↓ plasma
59 Hexanoylcarnitine (C6), Octanoylcarnitine (C8),Decanoylcarnitine (C10), Myristoylcarnitine (C14) ↑ plasma
60 Malonylcarnitine, Oleoylcarnitine (C18:1)
61 Suberoylcarnitine (C8-dicarb) ↑ plasma
62 Summed C10-C14 acylcarnitines ↑ plasma
63 2-methylbutyroylcarnitine ↑ plasma
64 3-dehydroxycarnitine ↑ plasma
65 Butyrylcarnitine (C4) ↓ plasma
66 Isobutyrylcarnitine ↑ plasma
67 Valerylcarnitine ↑ plasma
68 Isovalerylcarnitine ↑ plasma
69 3-Hydroxy-isovalerylcarnitine ↑ plasma
70 3-Methyl-crotonylcarnitine ↑ plasma
71 Hexanoylcarnitine (C6) ↑ plasma
72 Phenylacetylcarnitine ↑ plasma
73 Phenylpropionylcarnitine ↑ plasma
74 4-Phenyl-butyrylcarnitine ↓ plasma
75 4-Methyl-hexanoylcarnitine ↑ plasma
76 Octanoylcarnitine (C8) ↑ plasma
77 cis-3,4-Methylene-heptanoylcarnitine ↑ plasma
78 Decanoylcarnitine (C10) ↑ plasma
79 cis-4-Decenoylcarnitine ↑ plasma
80 cis-3,4-Methylene-nonanoylcarnitine ↑ plasma
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Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
81 Lauroylcarnitine (C12) ↑ plasma
82 Myristoylcarnitine (C14) ↑ plasma
83 Linoleoylcarnitine (C18:2) ↑ plasma
84 Adipoylcarnitine (C6-dicarb) ↑ plasma
85 Suberoylcarnitine (C8-dicarb) ↑ plasma
86 C18:2-carnitine ↑ plasma
87 C20-carnitine ↑ plasma
88 C20:4-carnitine ↑ plasma
89 C26-carnitine ↑ plasma
90
Organic acids
Malonate ↑ plasma Fatty acids metabolism
91 Lactate ↑ plasma Glycolysis
92 Acetate ↑ plasma Glycolysis, ala and asp metabolism
93 Valeric acid ↑ plasma Glycolysis, fatty acid b-oxidation
94 Formate ↑ plasma Glyoxylate and dicarboxylate
95 N1-Methylnicotinamide ↑ plasma
Nicotinate, nicotinamide metabolism
96 N1-Methylnicotinic acid ↑ plasma
97 Nicotinamide-n-oxide ↑ plasma
98 N-Methyl-2-pyridone-5-carboxamide ↑ plasma
99 N-Methyl-4-pyridone-3-carboxamide ↑ plasma
100 3-Ureidopropanoate ↑ plasma Purine metabolism
101 Orotate ↑ plasma Pyrimidine metabolism
102 Isocaproyl ↓ plasma Steroid and hormone production
103 (s)-Malate ↓ plasma/serum
TCA cycle metabolism
104 2-Oxoglutarate ↑ plasma/serum
105 cis-Aconitate ↓ plasma/serum
106 Citrate ↑ plasma/serum
107 Fumarate ↑ plasma/serum
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Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
108 Succinate ↑ plasma/serum
109 m-Hydroxyphenyl propionic acid ↑ plasma/serum
Phenyl alanine metabolism (bacterial)
110 m-Hydroxyphenyl propionic acid sulfate ↑ plasma/serum
111 Phenyl sulfate ↓ plasma/serum
112 Hippurate ↑ plasma/serum
113 5-Hydroxykynurenine ↑ plasma Amino acids metabolism
114 3-deoxyarabinohexonic acid ↑ serum Fatty acid metabolism
115 Uronic acid ↑ plasma/serum Glucose metabolism
116 Erythronate ↑ plasma Amino-sugars metabolism
117 Gluconic acid ↑ plasma Carbohydrate metabolism
118 Benzoic acid ↓ plasma/urine Phenolic metabolite
119 Acetic acid ↓ plasma/urine Carbohydrate metabolism
120 Propionic acid ↓ plasma/urine Carbohydrate metabolism
121 Butyric acid ↓ plasma/urine Carbohydrate metabolism
122 Isovaleric acid ↓ plasma/urine Carbohydrate metabolism
123 Valeric acid ↑ plasma/urine Carbohydrate metabolism
124 Succinic acid ↑ plasma/urine Carbohydrate metabolism
125 Formic acid ↑ plasma/urine Carbohydrate metabolism
126 Lactic acid ↑ plasma/urine Carbohydrate metabolism
127 Capric acid ↑ plasma/urine Carbohydrate metabolism
128 Caprylic acid ↑ plasma/urine Carbohydrate metabolism
129 Citrate ↑ plasma/urine Carbohydrate metabolism
130 Ethylmalonic acid ↑ plasma/urine Carbohydrate metabolism
131 Fumarate ↑ plasma/urine Carbohydrate metabolism
132 Glutaric acid ↑ plasma/urine Carbohydrate metabolism
133 Glycolic acid ↑ plasma/urine Carbohydrate metabolism
134 β-Hydroxybutyrate ↑ plasma/urine Carbohydrate metabolism
135 α-Hydroxybutyrate ↑ plasma/urine Carbohydrate metabolism
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Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
136 2-Hydroxyisocaproic acid ↑ plasma/urine Carbohydrate metabolism
137 α-Ketoglutarate ↑ plasma/urine Carbohydrate metabolism
138 Lactate ↑ plasma/urine Carbohydrate metabolism
139 Methylmalonic acid ↑ plasma/urine Carbohydrate metabolism
140 Orotic acid ↑ plasma/urine Carbohydrate metabolism
141 Oxalic acid ↑ plasma/urine Carbohydrate metabolism
142 Oxaloacetate ↑ plasma/urine Carbohydrate metabolism
143 Pyroglutamic acid ↓ plasma/urine Carbohydrate metabolism
144 Pyruvate ↑ plasma/urine Carbohydrate metabolism
145 Sebacic acid ↑ plasma/urine Carbohydrate metabolism
146 Suberic acid ↓ plasma/urine Carbohydrate metabolism
147 Succinate ↑ plasma/urine Carbohydrate metabolism
148 Lactate ↓ plasma/urine Carbohydrate metabolism
149 Hippuric acid ↑ plasma/urine Carbohydrate metabolism
150 Indole-3-carboxylic acid ↑ plasma/urine Carbohydrate metabolism
151 Phenyllactic acid ↑ urine Carbohydrate metabolism
152 Glyoxylate ↑ urine Energy metabolism
153 2-Hydroxybutyrate ↑ plasma/urine Energy metabolism
154 3-Hydroxybutyrate ↑ plasma/urine Energy metabolism
155 3-Hydroxy-3-(3-hydroxyphenyl) propanoic acid ↑ plasma/urine Energy metabolism
156 5-Hydroxymethyl-2-furancarboxylic acid ↑ plasma/urine Energy metabolism
157 Benzoic acid ↑ plasma/urine Energy metabolism
158
Free fatty acids
2-Hydroxy-N-valerate ↓ plasma/serum Fatty acids metabolism
159 Docosanoic acid ↑ plasma Free fatty acid synthesis
160 2-Hydroxyvaleric acid ↑ plasma Free fatty acid synthesis
161 C12:0 ↑ plasma
Lipid metabolism
162 C14:0 ↑ plasma
163 C15:0 ↑ plasma
164 C16:0 ↑ plasma
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Table 1. Cont.
Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
165 C16:1n-9 ↑ plasma
166 C16:1n-7 ↑ plasma
167 C18:0 ↑ plasma
168 C18:1n-9 ↑ plasma
169 C18:1n-7 ↑ plasma
170 C18:2n-6 ↑ plasma
171 C18:3n-3 ↑ plasma
172 C18:3n-6 ↑ plasma
173 C20:0 ↑ plasma
174 C20:1n-9 ↑ plasma
175 C20:2n-7 ↑ plasma
176 C20:3n-6 ↑ plasma
177 C20:4n-6 ↑ plasma
178 C20:5n-3 ↓ plasma
179 C22:1n-9 ↑ plasma
180 C22:4n-6 ↑ plasma
181 C22:5n-6 ↓ plasma
182 C22:5n-3 ↑ plasma
183 C22:6n-3 ↑ plasma
184
(Phospho)-lipids
LysoPC 16:0, 18:0 ↑ plasma Phospholipid metabolism
185 PE C34:2, PE C36:2, PE C38:4, ↑ plasma
186
DG 16:0/22:5, DG 16:0/22:6, DG 16:1/18:0, DG 16:1/18:1,
DG 16:0/16:0, DG 18:0/18:1, DG 16:0/18:0, DG 16:0/20:4,
DG 14:0/18:1, DG 16:0/20:3, and DG 18:0/18:2
↑ plasma Phospholipid metabolism
187
LysoPC C17:0, lysoPC C18:1, LysoPC (18:2), LysoPC
C20:4, Lyso C 22:6, LysoPC C18:3, LysoPC C20:5,
Lyso-PC Lyso-PC C20:C36:3, Lyso-PC C38:5, Lyso-PC
40:1, Lyso-PC C18:2, Lyso-PC C34:3, Lyso-PC C42:5,
Lyso-PC C40:6, Lyso-PC C44:5, Lyso-PC C44:4
↓ plasma Phospholipid metabolism
188 phosphatidylinositol (PI) (PI 38:4, 36:2, 36:3, 34:2) ↓ plasma Phospholipid metabolism
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Sr. no. (Parent)-Class of Compound Metabolites Nature of Variation Source Associated Pathway
189 phosphatidylethanolamine (PE) (PE 38:6, PE 38:5, PE38:4 and PE 36:3 ↓ plasma Phospholipid metabolism
190 Cholesteryl-β-d-glucoside ↑ plasma Phospholipid metabolism
191 Cholesteryl-β-d-glucoside fragment ↑ plasma Cholesterol metabolism
192 1,2 Distearyole phosphatidyle serine ↑ plasma Cholesterol metabolism
193 Lyso PE 18:2, LysoPE (20:0/0:0), LysoPE (20:2/0:0),LysoPE (20:1/0:0) ↑ plasma Phospholipid metabolism
194 TAG 52:1, TAG 50:0, TAG 48:1, TAG 46:1, TAG 44:1TAG 48:0 ↑ plasma Lipids metabolism
195 PC 34:2, PC 40:1, PC 36:3, and PC 38:5 ↑ plasma
196 SM 22:0 ↑ plasma Phospholipid metabolism
197 TAG 58:10, TAG 56:9, TAG 60:12 ↓ plasma Phospholipid metabolism
198 PC 38:6, 18:2, C34:4 ↓ plasma Phospholipid metabolism
199 TAG 50:0 + TAG 58:10 ↑ plasma Lipids metabolism
200 PC 22:4/dm18:0, PCO-20:0/O-20:0,PCO-18:0/22:5,LysoPCdm16:0 ↑ plasma Phospholipid metabolism
201 LysoPCdm16:0 ↑ plasma Phospholipid metabolism
202 GlcCer (d18:0/18:0) PC (16:0/O-16:0) PC (O-14:0/18:0) ↓ plasma Phospholipid metabolism
203 diacyl-PC36:1, PC32:1, PC40:5, and PC38:3 ↑ plasma Phospholipid metabolism
204 PC (18:2/dm16:0) PC (O-16:0/18:3) PC (O-16:0/18:3) ↑ plasma Phospholipid metabolism
205 PC (P-16:0/18:2) ↑ plasma Phospholipid metabolism
206 glycerophosphorylcholine [M] ↓ plasma Glycerolipids metabolism
207 PC a C20:4 (alt) [B] ↓ plasma Glycerolipids metabolism
208 PC aa (OH, COOH) C28:4 ↓ plasma Glycerolipids metabolism
209 PC aa C34:4 ↓ plasma Glycerolipids metabolism
210
SM C14:0, C16:1, SM C22:2, SM C18:1,
dihydroceramides d18:0/C18:0, d18:0/C22:0, ceramide
d18:1/C18:0
↓ plasma Glycerolipids metabolism
211 PE aa C34:2, PE aa C36:2, PE aa C38:4 ↑ plasma Glycerolipids metabolism
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212 Gangliosides C16:0 and C18:0 and glucosylceramides(C16:0, C22:0, C24:0 and C24:1) ↑ plasma Lipid/fatty acid metabolism
213 PC aa C34:4, PC 34:4 ↓ plasma Glycerolipids metabolism
214 arachidonate ↓ plasma Polyene metabolism
215
myristate (14:0), palmitate (16:0), oleic acid,
heptadecanoic acid, margarate (17:0), stearate (18:0),
10-heptadecenoate (17:1n7), oleate (18:1n9), linoleate
(18:2n6), linoleamide (18:2n6), linolenate (18:3n3 or 6),
eicosenoate (20:1n9 or 11), dihomo-alpha-linolenate
(20:3n3), adrenate (22:4n6), TG 14:1/16:1/18:0, TG
16:1/16:1/16:1
↑ plasma FA metabolism
216 cholesterol esters (CE) (CE 24:1, and CE 22:0) ↑ plasma FA metabolism
217 2-hydroxypalmitate ↑ plasma Medium-chain FA metabolism
218 2-hydroxystearate ↑ plasma
SFA metabolism219 caproate (6:0), heptanoate (7:0), pelargonate (9:0) ↓ plasma
220 10-undecenoate (11:1n1) ↓ plasma
221 arachidonate (20:4n6) ↓ plasma
222 3-hydroxybutanoic acid (b-hydroxybutryrate) ↑ plasma Lipid/fatty acid metabolism
223 20-Hydroxy-leukotriene E4, 5-methoxytryptamine,Endomorphin-1 ↑ plasma Lipid/fatty acid metabolism
224 2-ketoisocaproic acid ↑ serum Lipid/fatty acid metabolism
225 α-hydroxyisobutyric acid ↑ serum Lipid/fatty acid metabolism
226 β-hydroxybutyric acid ↑ serum Lipid/fatty acid metabolism
227 1-monopalmitin ↑ serum Lipid/fatty acid metabolism
228 1-monostearin ↑ serum Lipid/fatty acid metabolism
229 Cholic acid ↑ urine Lipid/fatty acid metabolism
230 Suberic acid ↓ urine Lipid/fatty acid metabolism
231 Glycocholic acid ↑ urine Bile acid metabolism
232 3,4,5-Trihydroxypentanoic acid ↑ plasma/serum Lipid/fatty acid metabolism
233 Galactonic acid ↑ plasma/serum Lipid/fatty acid metabolism
234 2-Hydroxyglutaric acid ↑ plasma/serum Lipid/fatty acid metabolism
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BCAA: the first report of BCAA (i.e., valine, isoleucine, and leucine) correlation with insulin
resistance, impaired insulin signaling and diabetes appeared in 1970 [30]. Since then, an overwhelming
number of published data have advocated the predictive and pathogenic relationship of increasing
plasma BCAA concentration with obesity, insulin insensitivity and diabetes. The literature assertions
of higher plasma BCAA levels are mainly due to the concept of insulin resistance resulting from
the activation of the rapamycin molecular target (mTOR). It is currently poorly understood which
mechanisms are involved in increasing the BCAA level. However, most of the mechanistic work on this
topic cited the downregulation of mitochondrial branched-chain keto acid dehydrogenase (BCKDH)
and branched-chain aminotransferase (BCATm) expression followed by under-transamination and
thereafter under-decarboxylation and under-dehydration of BCAA [31]. Many in vitro and in vivo
studies stated that increasing BCAA (especially leucine) encouraged the insulin resistance by the
activation of mTORC1 and S6 kinase followed by the phosphorylation of insulin receptor substrates
S1 and S2. The deprivation of individual BCAA can promote the activity of mTORC1/S6K and
adenosine monophosphate-activated protein kinase (AMPK) signaling pathways resulting in improved
insulin sensitivity [32,33]. The prospective roles of reporting biomarker BCAA + aromatic AA in
the pathogenesis of T2DM were further investigated in a Finnish cohort study stating the BCCA
+ aromatic AA as an early predictor of insulin resistance in young Finnish adults after 6 years of
follow-up study [34]. A recent cohort study on 3000 volunteers found BCAA to be a valid indicator of
the future risk of DM [20]. Various prospective, case-controlled and nested studies on the subjects of
different ethnicities found elevated levels of BCAA in the pre-diabetic, insulin-resistant and T2DM
subjects [35,36]. The longitudinal nested control-case study conducted on UK Caucasians found three
BCAA as early predictors of T2DM risk [17]. A 12-year follow-up study found 2.5- to 3.5-fold higher
odds of T2DM risk in the top quartiles of individuals as compared to those individuals whose plasma
amino acids were in the lowest quartiles. The adjustments of predictive models for parental history,
dietary variations and serum triglycerides further elevated the odds ratios of metabolites, especially
amino acids. The replication analysis with Malmo and cancer diets also established a substantial
relationship of four amino acids (leucine, tyrosine, valine, and phenylalanine) with incidence of
diabetes. In Malmo diets, the three amino acid combination (isoleucine, tyrosine, phenylalanine)
quadrupled the incident of diabetes compared to lowest quartiles [17]. Tillin et al. [19] conducted a
multi-ethnic cohort study for a 19 year period of follow-up and witnessed that 14–35% of the population
who had shown higher BCAA level at baseline developed T2DM. The logistic regression results of this
study clearly bespoke about the obvious involvement of BCAA (odds ratio (OR) = 3.14 to 3.36) in the
development of diabetes. Chen and his colleagues also reported that after 10 years of follow-up, a
higher positive correlation was detected between the baseline five BCAA and incidence of DM in the
understudied Chinese population [37]. The seven years of follow up in the EPIC-Potsdam cohort study
found a positive correlation between future DM risk and valine, isoleucine and leucine [28]. A similar
study was also performed on the Chinese Han ethnic folks who are among the highest diabetes
vulnerable group [38]. This study verified the prediction-ability of a chosen model and proposed higher
levels of alanine, lactate, β-hydroxybutyric acid, phosphate, leucine, α-hydroxyisobutyric acid, serine,
isoleucine, palmitic acid, pyroglutamic acid, stearic acid, oleic acid, 1-monopalmitin, arachidonic acid
and 1-monostearin while substantial lower levels of 2-ketoisocaproic acid as early biomarkers of T2DM.
Similarly, Fiehn et al. [35] noted a 50% higher concentration of plasma leucine with a 27% higher
amount of its catabolic secondary metabolite called 2-ketoisocaproic acid (α-ketoisocaproate). The mean
concentration of plasma valine was 20% higher in pre-diabetic weight/age matched African-American
ethnical subjects. The enrichment of the plasma AA pool with valine and leucine is also strongly
correlated with the plasma acetyl-carnitine concentration. The AA score (sum of BCAA + aromatic AA)
was found to be in association with baseline insulin resistance/HOMA-IR even after the adjustment
for metabolic factors. The magnitude of this association was found to be more pronounced for men
than for women. The authors stated that both the BCAA + aromatic AA were strong predictors
of insulin insensitivity in men, whereas only valine, leucine and phenylalanine showed a positive
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correlation for HOMA-IR in women [22,35,39]. Stancakova et al. [22] observed that among all BCAA,
isoleucine was found to be strongest and most reliable predictor of insulin resistance. Some studies
concluded that fasting plasma BCAA levels are a reliable predictor of T2DM, whereas circulating
BCAA correlated positively with the indices of uncontrolled blood glucose and insulin resistance
in overweight individuals [40]. Some studies also documented the correlation of plasma BCAA is
only significant in prediabetic obese subjects who started losing significance upon losing weight and
improving insulin sensitivity [41]. Other work has also stated the BCAA is solely responsible for
insulin resistance, at least under the circumstances of high tissue FA availability and in high-fat feeding
conditions [33]. With respect to age, no obvious difference was noted in the correlation of BCAA with
insulin resistance between youth and adults’ subjects [42]. Although an ethnicity based studies came up
with some mixed conclusions. The cohort studies on the Asian population experienced and supported
BCAA as a validated biomarker for the prognosis and development of T2DM [19,43,44], whilst, at
the same time a predictive model study in American-Indians failed to developed a reporter BCAA
notion [45]. The difference in the predictability of BCCA for the future risk of DM in different ethnicities
(Caucasian Hispanic and Africans Americans) was further investigated by Lee et al. [46] and dictated
that diabetic risk was more prevalent among the Hispanic Caucasians compared to African Americans.
Chen et al. [21] recently conducted plasma metabolomics on the subjects recruited from the SHDS
cohort study in which they identified increased (2-folds) BCAA even at baseline between the future
diabetic patients and the healthy controls. The fitting of basic and advanced regression models to these
BCAA metabolites with 3–14 confounding factors verified the correlation of BCAA with the future
risk of diabetes without any dependence on physical activity factors. The discrimination between the
healthy and diabetic groups was also evident in the area-under-curve (AUC) interpretations of these
BCAA. As expected, the regrouping of diabetic and healthy controls also exhibited a strong relationship
of BCAA with diabetes in diabetic people with fold change (FC) >2 and odds ratio (OR) >1.5 [21].
Subsequently, the correlation of the worsening of metabolic control of glucose with the BCAA was
investigated, which was important to confirm further the BCAA status of a validated early biomarker
of diabetes. The authors used the UCD-T2DM rat models, which were homozygous for β-cell defects
with diabetes-prone obese ancestors [41,47]. Piccolo and his colleagues asserted that metabolites
of BCAA are more robust markers of insulin resistance than BCAA themselves. 2-ketoisocaproate
and 2-hydroxybutanoic, the metabolites of leucine and methionine/cysteine respectively, have been
implicated as the most reliable markers of diabetes risk as these metabolites were lower before the
onset of insulin resistance and their level increased just after 3 weeks of detected metabolic insulin
resistance. Besides BCAA, all other gluconeogenic and ketogenic amino acids (i.e., alanine, glycine,
methionine, serine, thrionine, trypsine and ornithine) were found to have been reduced by 16–36%
in the pre-diabetic UCD-T2DM rat model. The plasma BCAA correlation with total fasting plasma
glucose, adiposity and insulin become more significant with the worsening of the metabolic control
of glucose [41,47]. In addition to the work of Piccolo et al. [41,47], many metabolomics studies also
established the fact that catabolic products of BCAA also have equal predictive qualities to BCAA.
The BCAA-derived short-branched fatty acid and branched-chain keto acids are new to this list.
The odd carbon number acylcarnitines, another BCAA breakdown products, are also considered as the
latest reported biomarker of insulin resistance development [48,49]. However, the only disadvantage
with BCAA-derived metabolites is having a lower plasma/tissue concentration and stability than
BCAA, resulting in higher analytical variations. The intake of BCAA with a high-fat diet for 9–16
weeks increased (2.3- to 3.1-fold) subcutaneous/visceral fat mass and respiratory quotient (RQ),
HOMA-IR in obese Wister rats followed by up-regulation of 14 energy metabolism-related hormones
(glucagon-like peptide-1 (GLP-1), amylin, pancreatic polypeptide, resistin and insulin-like growth
factor binding protein-3-IGFBP-3). The evaluation of BCAA related metabolites and HOMA showed a
linear correlation, which signified the BCAA responsible for obesity-related morbidities. Like HFD,
BCAA diets contributed equally towards the development of insulin resistance as HFD, HFD + BCAAA
and BCAA diets impaired the phosphorylation of AKT/protein kinase B in individual experiments.
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A BCAA rich diet equally raised insulin resistance and weight gain like HF diets, but the addition of
BCAA in HF diets reduced food intake [32,50]. Please note that diabetic and obesity-promoting effects
of BCAA are only possible when all three BCAA were used in combination and supplementation of
single BCAA usually does not increase the insulin resistance [51]. Many studies documented a reduced
level of other AA after the increase of BCAA and aromatic AA. In this context, the most favorable idea
is that higher BCAA plasma levels (in insulin-resistant cases) markedly reduce the catabolism in main
tissues which, in turn, limits the obligatory AA concentrations in tissues considered responsible for
normal metabolism. There are also many reports in the literature supporting this school of thought and
indicating the reduced expression and activities of two initial catabolic BCAA enzymes (branched-chain
amino acid aminotransferase-BCATm branched-chain a-ketoacid dehydrogenase-BCKD) in the liver
and adipose tissue. T2DM patients also showed a 20% less whole-body clearance of BCAA [52,53].
Literature has also shown the declining outcome of the impairment of BCAA oxidation or turnover in
T2DM or obese people [54]. In fact, additional work is needed to find the exact reasons for elevated
levels of BCAA (if any) and to track down the fate of proteins and BCAA metabolism in diabetic
and obese subjects. The plasma biotin status is also crucial for catabolic carboxylation enzymes
of cysteine, TCA cycle anaplerosis and BCAA. Low biotin levels were found in insulin resistant
patients with higher 2-hydroxybutyric acid (2-HB) metabolite. The higher 2-HB concentration induced
the dysfunctional bioactivity of biotin tissues which in turn affects the cysteine/BCAA/TCA cycle
anaplerosis metabolism [35]. In summary, the plasma concentration of BCAA has a positive relation
with the future risk of T2DM. The comparative predictive-power of BCAA may vary with leucine and
isoleucine cited as relatively the most powerful reporter BCAA biomarker of T2DM. The level of BCAA
enabling this group of metabolites to be considered as a reliable biomarkers needs to be defined with
respect to sex and ethnicities. The intake of BCAA could pose serious health problems in individuals
with unknown insulinemia, dyslipidemia and glycemia.
4. Biomarkers of Disturbed Lipid Metabolism
Homeostasis of lipid metabolism is a tightly regulated act at various molecular and cellular levels
in healthy subjects whereas obesity is the central risk factor for disturbances in homeostasis of lipid
metabolism (hence T2DM pathogenesis) leading to the accumulation of excess fat, dysregulated glucose
and lipid metabolism, impaired insulin and adipocyte signaling, and various other pathologies related
to cardiovascular disease, arthrosclerosis and inflammation. This alternation in the lipid metabolism at
the cellular level usually occurs years before the diagnosis of diabetes. Many studies in the literature
cited this varied window-period from altered lipid metabolism to a final diagnosis of T2DM in many
cohort studies related to biomarkers. These biomarkers belong to dynamic classes of lipids but we,
for the convenience of readers, will state only those signature early biomarkers of T2DM risk which
belong to the three main classes of lipids.
Glycerolipids and phospholipids (PL): high-density-lipoprotein-cholesterol (HDL-C),
low-density-lipoprotein-cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC) and BMI
are the typical dyslipidemic risk factors/biomarkers for T2DM. However, recently, several cohort
studies focused on the lipidomics of the subjects for finding novel biomarkers of T2DM.
All these lipidomics studies found varying quantities of diacyl phosphatidylcholines (PC),
glycerophospholipids (GPL), phosphatidylethanolamines (PE), alkylacyl phosphatidylcholines (PC),
lysophosphatidylcholines (LysoPC), alkylacyl phosphatidylethanolamines (PE), triacylglycerols (TG),
lysophosphatidylethanolamines (LysoPE), sphingomyelins (SM), cholesterol esters (ChoE) and
ceramides (Cer) in the (pre)diabetic compared to non-diabetic patients [3,4,55–59]. These lipid
metabolites are diabetic risk predictors in human beings. To investigate the mechanism by which
these lipids contribute to the prediction of diabetic risk, many studies compared the lipidome
of (pre)-diabetic persons with healthy controls in several cohort studies with a follow up of
≥5 years. A prospective case-control cohort study on European Caucasians identified 34 metabolites
significantly associated with the early risk of T2DM. The risk of T2DM was positively associated
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with phenylalanine, hexose, and diacyl-phosphatidylcholines (36:1, 32:1, 40:5 and 38:3), while an
inverse relation was detected with sphingomyelin (16:1), glycine, acyl-alkyl-phosphatidylcholines,
lysoPC (18:2) as well as PC (34:3, 42:5, 40:6, 44:5 and 44:4) (Table 1) [28]. The unsupervised PCA
divided the metabolites into two metabolic factors. Metabolite factor 1 (i.e., sphingomyelins,
acyl-alkyl-phosphatidylcholines and lysophosphatidylcholines) reduced the incidence of T2DM by 69%
and metabolite factor 2 (i.e., BCAA, diacyl-phosphatidylcholines, propionyl carnitine, aromatic amino
acids, and hexose) increased the risk of T2DM almost 4 times. [28]. Some metabolites of phospholipid
metabolism (lysophosphatidylcholine C18:2, acyl-alkyl-phosphatidylcholines, and glycine) were
found in hyper-insulin-sensitivity cases whereas some phospholipid metabolism metabolites (e.g.,
diacyl-phosphatidylcholines, acyl-alkyl-phosphatidylcholines, sphingomyelin C16:1) were associated
with insulin resistance and less insulin secretion. It is worthy to note that choline derived phospholipids
were significantly associated with the risk of T2DM [60,61]. These kinds of phospholipids also
acted as a potent antioxidant to prevent the oxidation of lipoproteins and also required for the
secretions of VLDL and VHDL from hepatic tissues [62]. These choline derived phospholipids are in
a positive relationship with the serum HDL and any dietary deficiency of choline can lead to blood
scarcity of phospholipids and hence HDL. Higher levels of acyl-alkyl-phosphatidyl choline (except
diacyl-alkyl-phosphatidyl cholines) also correlated with reduced TG blood level and with improved
insulin sensitivity. However, the shorter chain and saturated phosphatidylcholines are positively
associated with the risk of T2DM and longer chain unsaturated phosphatidylcholines are protective
against it (Table 1) [63]. Wang-Settler et al. [4] also identified low levels of LysoPC 18:2 and glycine
as an early indicators of the onset of T2DM in a prospective crested case-controlled study. Suhre
et al. [64,65] also identified numerous glycerophospholipids associated with the T2DM risk in the
KORA F3 case-controlled cohort study. The PCs (34:4, 36:3, 38:5, and 40:1) and LysoPC (20:4) are
negatively associated with diabetes. On the other hand, Pes (34:2, 36:2 and 38:4) of the same carbon
chain lengths increased in diabetic subjects. The METSIM (Metabolic Syndrome in Men), a prospective
population cohort study, adopted a global lipidomic profiling approach and found elevated levels of
one PL cluster (LC8), 4 TG clusters (LC9 to LC12) and a decreased concentration of ether alkylacyl
phospholipids (PL) cluster at baseline in undiagnosed prediabetic-progressors [58]. The dyslipidemia
biomarkers (LDL-C, HDL-C, ALT and total TG) have also shown a positive correlation with the
TG clusters (LC9 to LC12), whereas a negative correlation with PL cluster (LC5) and arachidonic
acid containing PCs. The lipid profile of normal glucose tolerance (NGT)-non-progressors was
similar to the prediabetic non-progressors both at baseline and at the end of a five-year follow-up.
LysoPC, SM, highly-unsaturated LCTGs and ceramide-containing lipid clusters increased in prediabetic
non-progressors compared to healthy-non-progressors [58]. Rhee and his team correlated dyslipidemia
and risk assessment of diabetes incidence. A strong association of TG with a single double bond
and low carbon number with the risk of T2DM has been witnessed by Rhee and his colleagues [66].
The short-chained monounsaturated TG were linked with the high prevalence rate of diabetes, whereas
large carbon number monounsaturated TG were related to a reduced risk of diabetes. The multivariate
adjustments of a regression model with LysoPE, PC, SM and diacylglycerols (DAG) retained the
same results. A total of 9 analytes were screened after the regression analysis adjustments with
respect to age, sex, BMI, fasting insulin, cholesterol and parental history. With each increment in
the SD of the odds ratios of these nine metabolites, the prospects of diabetes incidence increased
by 1.35–1.94-fold. The acute studies with exercise and even with administration of glipizide, have
also shown that short chain unsaturated TG decreased with OGTT and long chain unsaturated TG
increased (Table 1) [59,67]. The plasma levels of these TG were further corroborated with the insulin
resistance. The TG levels were found to differ abruptly and differently over the course of studies
consisting of 12 years. The integration of negative and positive risk factors of TG with relatively
higher carbon numbers and unsaturation index improved the prediction ability of the used model [68].
However, it is still the subject of investigation whether these lipids served only as diabetes predictors
or also contributed towards the pathogenesis of DM. In addition to TG, the logistic regression-based
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predicting models were also proposed for identifying and predicting PL-based-biomarkers in the
discovery and validation of cohort sets. These models proposed LysoPC (18:2), LysoPC (32:1), LysoPC
(34:2e), TG (17:1),TG (50:5) TG (50:1), TG (18:1), TG (54:5), TG (18:2), TG (56:4) and ether lipid PC
(42:6e), as validated biomarkers for early diagnosis/prediction of T2DM [58,59]. Similar kinds of
outcomes have been reported by the RISC and Botnia cohort studies which described a reciprocal
relationship of LysoPC (18:2) with the risk of T2DM. The fasting plasma level of LysoPC (18:2) measured
at baseline independently predicted the risk of T2DM with the same power as of 2 h plasma glucose
level [69]. The AusDiab cross-sectional cohort study of undiagnosed T2DM patients also showed an
increased AUC for 17 lipid risk factors belong to five classes of lipids i.e., diacylglycerols (DG) (DG
16:0/22:5, 16:0/22:6, 16:1/18:0, 16:1/18:1, 16:0/16:0, 18:0/18:1, 16:0/18:0, 16:0/20:4, 14:0/18:1, 16:0/20:3, and
18:0/18:2), TG (14:1/16:1/18:0, 16:1/16:1/16:1), cholesterol esters (CE) (CE 24:1 and CE 22:0), PE 40:6
and dihydroceramide (DHC) (dhCer 18:0). The inclusion of DAG, in addition to TG and Hb1Ac,
in the predicting models significantly improved the independent stratification of patients of impaired
glucose tolerance (IGT) from the whole population of NGT. The incorporation of DHC, PEe and
CE not only represented elevated levels of TG in potential IGT patients but also reflected separated
biological processes in prediabetic patients compared to healthy ones [70]. Stahlman et al. [71] also
unveiled the increased composition of DG (16:0/22:5, 16:0/16:0 and 16:0/22:6) and triacylglycerol
species in the VLDL-C and LDL-C diabetic dyslipidemic women. Another cross-sectional explorative
cohort study on age and health matched lean and obese (prone to T2DM) human subjects, disclosed
that abundance of six metabolites varied considerably between the lean and obese persons and
considered the predictors of body fat mass. The lipid metabolite (PC 42:0) was found to be abundant
in the obese subjects whereas PC (32:1), PC 32:0, and PC (40:5) were higher in the lean subjects [57].
The rest of the lipid-based body fat mass predictor metabolites belong to carnitines and have been
described in their respective section. The relationship of obesity with T2DM was further dissected
by the metabolomics done by the team of Tulipani et al. [72]. This study unveiled the relationship
of glycemic impairment with obesity based on the three lysoPC. These three lysoPC i.e., lysoPC
(17:0, 18:1, and 18:2), showed a strong inverse correlation with BMI, body weight, hip circumference
and waist. The levels of these lysoPC decreased in those obese subjects who were in the highest
quartile i.e., more prone to develop diabetes. The serum phospholipids also showed the same nature of
relationships with the dyslipidemic biomarkers however, this relationship was less significant than that
of lysoPC [72]. Tulipani and his colleagues also described the elevated levels of nonpolar sphingolipids
(dihydro)ceramides (d18:0/18:0 and d18:0/22:0), ceramide (d18:1/18:0) and sphingomyelin (18:0) in
those human subjects which later developed T2DM. Suhre et al. [64] conducted a fully comprehensive
metabolomics study on a subgroup of T2DM diabetic males (55 years old) of the KORA F3 cohort.
This study described phosphatidylcholines PC (34:4) and the lysoPC (20:4) in reciprocal relationship
with the risk of T2DM whereas PC with PUFA side chains i.e., PC (40:1, 36:3 and 38:5) were found
to be in a positive relationship with T2DM. At the same time, PE with the same side chain length
i.e., PE (34:2, 36:2 and 38:4) were found increased in the T2DM patients [64]. The individuals with
single nucleotide polymorphism (SNP), another greater risk factor for T2DM, also showed elevated
levels of non-esterified fatty acids (NEFAs), acylcarnitines (C2 and C3), several SM, lysoPC and PC in
rs7903146 risk allele carriers. The list of metabolites which were observed down-regulated includes
SM-OH (24:1), lysoPC (16:0, 16:1 and 17:0) [73]. The difference in PC level between different genotype
groups was not significant; however, the unsaturated PC were down-regulated significantly in the
SNP-transcription factor 7-like 2 (TCF7L2) group [73]. In an attempt to discriminate the human
subjects with NGT, pre-diabetes and T2DM, Zeng et al. [74] found five classifiers metabolites, i.e.
20-hydroxy-leukotriene E4, LysoPC 20:4, 5-methoxytryptamine, Endomorphin-1 and LysoPC 20:3
between NGT and pre-diabetic groups. Similarly five other metabolites i.e., iso-valeraldehyde, linoleic
acid, LysoPC (18:1), 2-pyrroloylglycine and dityrosine were found to be strong discriminators between
the pre-diabetic and diabetic subjects. The plasma level of PC (18:3/20:3) was found to be increased in
pre-diabetes in comparison to NGT subjects whereas PC (18:0/18:2 and 16:0/14:0) reduced in pre-diabetes
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in comparison to T2DM. Various lysoPC species i.e., lysoPC (20:4, 18:3, 20:5 and 20:3) were also found
to be decreased in T2DM patients in comparison to pre-diabetes [74]. Another, recently published work
found altered classes of glycerophopsholipids, nucleotide and (deoxy) sugars in the large prospective
nested case-controlled study in diabetic and non-diabetic patients. Out of >1300 detected metabolites
only 34 were found higher in diabetic patients throughout the study period. Among lipid-based
classes, only six metabolites (i.e., PC (22:4/dm18:0, O-20:0/O-20:0 and, O-18:0/22:5) as well as LysoPC
(16:0)) showed strong association with T2DM risk. The individuals within the highest tertiles of these
metabolites were found to be 4-fold more prone to T2DM [75]. Zhao and his colleagues conducted
a cohort study on 3665 American Indians (sixty-five 3-generation and 29 two-generation families),
which lasted for 5.5 years [45]. Approximately 9.3% of people became diabetic, whereas 7.5% of the
population developed impaired fasting glucose during the study duration. The study found new
metabolic lipid-based biomarkers which significantly can predict the risk of T2DM. A total of seven
metabolites (PC (22:6/20:4), 3S-7-hydroxy-29, 39, 49, 59, 8-pentamethoxyisoflavan (HPMF), MEIR,
LDYR, X-490, 2-hydroxybiphenyl (2HBP) and X-1178) were found in significant association with
T2DM risk. The 2HBP and m/z ratio 1178.804 (X-1178, unknown) were found in significant positive
association with T2DM risk. Whereas the other 5 detected biomarkers (HPMF, PC 22:6/20:4, two
peptides Met-Glu-Ile-Arg and Leu-Asp-Tyr-Arg, and metabolite m/z ratio 490.816 X-490) were found
in persons with a decreased risk of T2DM [45]. The study conducted by Conor and his colleagues [76]
reported similar results as Zhao et al. [45]. This work disclosed 80–89% higher odds ratios with each
rise in the SD of 2HBP and X-1178 (unknown metabolite). On the other hand, 32–42% less risk of T2DM
incidence was noticed with each SD increase in HPMF, peptides and PC PC22:6/20:4. García-Fontana
et al. [77] also segregated the T2DM with CVD, T2DM without CVD, and control healthy human
subjects based on four phospholipids metabolites. These four metabolites were PC (16:1(9Z)/2:0),
O-12:0/2:0), LysoPC (O-16:0/0:0), and LPE (18:2(9Z,12Z)). These four metabolites, belonging to three
different phospholipids classes, were found decreased in concentration in the T2DM patients. While
two metabolites, namely LysoPE (18:2(9Z,12Z)) and LysoPC (O-16:0) discriminated diabetic and
diabetic with CVD patients. The levels of these metabolites were further decreased in the diabetic with
CVD patients compared to only diabetic patients [77]. The consumption of HFD also induced the
specific validated biomarker of pre-diabetes which can be used to predict future risk of T2DM. Wigger
et al. [78] fed the six diabetic and obese mice models (DBA/2J, C57BL/6J, Balb/cJ, AJ, 129S2/SvPas,
and AKR/J) for a period of three months to check the response of varying genetic background to
lipid consumptions. In PL, 3 ceramides, 2 lactosylceramides, and 1 dihydroceramide showed a
constructive relation with HOMA-IR and fasting insulin levels whilst six-lipid species showed a
negative correlation with the insulin sensitivity suggesting these metabolites as early biomarkers of
(pre)-diabetes owing to HFD consumption. This targeted ceramide metabolomic intervention disclosed
the elevated levels of Cer (d18:1/18:0, d18:1/20:0 and d18:1/22:0) three years before the diagnosis of
T2DM. The plasma concentration of dihydroceramide Cer (d18:0) was found increased 9 years ahead
of T2DM occurrence. These findings were further validated by the targeted ceramide profiling in
plasma of another CoLaus cohort study which also confirmed the elevated plasma Cer (d18:0) levels
from baseline in the diabetic group compared to healthy ones [78]. Moreover, the oversupply of
saturated fats in sedentary subjects is known to induce the accumulation of ceramides as a result of
up-regulation of sphingolipids biosynthetic pathways (Figure 1) [79]. The accumulation of ceramides
promoted insulin resistance by down-regulating the activity of glucose uptake facilitator Akt/PKB [80].
Among many ceramides’ species, two recent and independent studies pinpointed the 16:0 ceramide
as main component inducing insulin resistance [81]. The plasma lipidomic of HFD-fed diabetic
C57BL/6J mice showed a significantly higher 16:0 ceramide level in the study group than in the control
group mice [82]. The 16:0 ceramide expression levels were up-regulated in the liver, white adipose
subcutaneous tissue, and brown adipose tissue of obese mice compared to lean mice, both on HFD.
At the same time, the knockout of 16:0 ceramide in HFD fed C57BL/6J mice significantly improved
insulin sensitivity, energy expenditure and glucose homeostasis [83]. The suggested mechanism of
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ceramide (over)-biosynthesis involves the dysfunctionality of adipose tissues resulting in excess
production of fatty acid precursors of ceramides and DAG which in turn activate the protein kinase
C (PKC) notorious for halting insulin signaling in muscles and liver. The inhibition of ceramide
biosynthesis also promoted the conversion of white adipose tissue to brown adipose tissue and
hence improved lipid and glucose metabolism [84]. Of note, ceramides serve as building blocks
of complex sphingolipids like glycosphingolipids and sphingomyelins and this involves a complex
set of biochemical reactions catalyzed by serine palmitoyltransferase (SPT). The AA serine can
be replaced with l-alanine to carry out this reaction which results in the formation of neurotoxic
1-deoxysphingolipids. The levels of 1-deoxysphingolipids were also found elevated in the plasma
of pre-diabetic and diabetic patients. On the basis of these findings, Othman et al. [85] found that
the 1-deoxysphingolipids (1-deoxysphingosine (1-deoxySO) and 1-deoxysphinganine (1-deoxySA))
can be used as early biomarkers/risk factors of T2DM. The plasma metabolomics of adult Rhesus
monkeys fed on high-fat/fructose-diet for a period of 8–66 months also exhibited the same elevated
levels of dihydroceramides and ceramides as obese pre-diabetic and diabetic mice [86]. The noted
ceramides species which increased enormously in the pre-diabetic/diabetic include 14:0, 16:0, 22:0 and
24:0 compared to controls. Ceramides are believed to be further metabolized into sphingosine (Sph),
sphingomyelin (SM), sphingosine-1-phosphate (S-1-P), sphinganine (Sa) and sphinganine-1-phosphate
(Sa-1-P) (Figure 1). The plasma level of Sa and Sph were severely elevated in the diabetic monkeys
whereas the levels of these metabolites remained unchanged in the prediabetic monkeys compared to
healthy control monkeys. S-1-P was also found to be increased in both diabetic/prediabetic groups
whereas Sa-1-P remained unchanged [86]. Gangliosides are a downstream products of ceramides
and also belong to sphingolipids. The plasma levels of two gangliosides (16:0 and 18:0) and four
glucosylceramides (16:0, 22:0, 24:0 and 24:1) were also found to be elevated in both the prediabetic
and diabetic groups compared to controls. The Spearman’s correlation analysis showed a negative
relationship between the HOMA-IR and total ceramides, deoxy-sphinganine and 14:0, 16:0, 22:0, 24:0
ceramides [86]. Similar results have been reported previously by the Huas et al. [87] who reported the
elevated levels of 18:0, 20:0, 24:1 and total ceramide in the type 2 diabetic human subjects. Elevated
levels of myristic, palmitic, stearic, linoleic, oleic and arachidonic acids were also pinpointed by the
Xu et al. [88], however, Xu and his colleagues mentioned a decreased level of glycerophspholipids
in persons in transition from NGT to IFG. This discrepancy in these results might arise due to the
inclusion or exclusion of certain covariates which ultimately affected the final results. The plasma
lipidome of (diabetic/non-diabetic) cynomolgus monkey also proposed different plasma polar lipids
biomarkers for the prediction of T2DM. This study found elevated levels of phosphatidylglycerol (PG)
and PC accompanying lowered plasma concentrations of phosphatidylinositol (PI) (PI 38:4, 36:2, 36:3,
34:2), and PE (38:6, 38:5, 38:4 and 36:3) [89].
Gestational diabetes (GDM) is a condition of high-blood-sugar in healthy pregnant women.
GDM affects 3–9% of global pregnancies and women with GDM are considered at an increased risk
of developing T2DM. The TG, PL and TC are found to increase in the last trimester of pregnancy.
In pregnant GDM subjects, the relative levels of TG were higher than the normo-glycemic pregnant
women [90]. Lu and his colleagues [91] identified five positively correlated predictor lipid species
i.e., TG (48:1), TG (51:1), and PC (32:1) and two negatively correlated i.e., choline ether phospholipid
(PCae) (40:4) and PCae (40:3) with post-load glucose levels. After the adjustment of maternal BMI,
age and correction of multiple testing, only the PCae (40:4) were found to be significantly associated
with GDM [92]. The correlation of TG (48:1), TG (51:1), and PC (32:1) with T2DM has also been
reported previously in the Framingham cohort study which described the elevated levels of these
three lipid species in diabetic AusDiab subjects [92]. The presence of these three lipid species which
possess a single double bond also implies the existence of monounsaturated fatty acids (MUFA)
(i.e., palmitoleate and oleate) in the LCMS spectra. In another cohort study, the hepatic formation of
palmitoleate and oleate and circulating plasma palmitoleate and oleate levels have been linked to T2DM
risk [93]. Recently, Petry et al. [94] also explored the paternally transmitted genotype and maternal
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lipid metabolomics revealing considerable associations of TG (44:1) with maternally transmitted fetal
imprinted alleles affecting the maternal glucose metabolism during pregnancy starting from the end of
the first trimester. This lipid was found associated with insulin resistance in the Framingham Offspring
Study too [66,68]. The abundance of TG (44:1) around the 15th week of pregnancy was seen as a
risk factor for GDM. Furthermore, a strong correlation was found between the HOMA-IR and TG
(44:1) in the DISCOVERY cohort study too. Increased serum levels of total fatty acids, TG, linoleic,
arachidonic, esterified cholesterol, glycolytic and Krebs cycle metabolites, 1,5-anhydroglucitol, glucose,
palmitoleic, FA derivatives, lysophospholipids, taurine-bile acids and docohexaenoic acids were also
witnessed in GDM females compared to NGT females [95,96]. The data-driven approach also identifies
distinguishing phospholipids i.e., (LysoPC (16:2), PC (36:3), PG (40:5), PC (48:1), LysoPC (18:0), PC
(19:0), PC (32:3), LysoPC (16:0), PC (14:1/dm16:0), PE (15:0/dm18:1) PC (34:6), PC (36:1) and LysoPC
(17:0)), long-chain/short-chain fatty acids (LCFA/SCFA) among pregnant women with GDM history,
women with NGT (control) and women with NGT but in the upper quartile of glycemic distribution.
The metabolites of phospholipids and LCFA/SCFA were higher in the control group compared to the
group at the upper quartile. Comparing the GDM group with the upper quartile group, 72 unique
metabolic features were identified in which 2-oxoglutaramate metabolite was twice as abundant in
GDM than those in the upper quartile group [97]. A nested, pair-matched, case-control study on
the GDM women of the Study of Women, Infant Feeding and Type 2 Diabetes after GDM Pregnancy
(SWIFT) cohort participants successfully developed a prediction model of GDM-to-T2DM transition,
with 83% discrimination power (AUC), comprising of a four-structure metabolic signature (a) hexoses,
(b) PC (40:5), (c) BCAA, and (d) SM (14:1) (OH) [98]. The GDM pregnant women of the SWIFT cohort
also exhibited lowered levels of PC and sphingolipids than normal healthy controls [99]. Additionally,
smaller nested case-controlled study also proposed another validated prediction model consisting of
six general dyslipidemic risk factors and three polar lipid metabolites i.e., phosphatidylserine (PS)
38:4, PE (P-36:2) and cholesteryl ester (CE) 20:4 [100]. The univariate receiver operating characteristic
(ROC) analysis in a nested, case-controlled, pair-matched study of Asian and Hispanic origin women
discovered the elevated levels of fasting triacyglycerlas (TAG) at baseline in those subjects who
developed T2DM in a follow up of two years [101]. The multivariate-ROC analysis deliberately
exhibited 12 lipid metabolites belong to TAG, ceramide, NEFA, lactosylceramide (LCer), LPC, LPE,
PE and SM classes of lipids. The TAG (myristic acid (14:0), palmitic acid (16:0), stearic acid (18:0),
oleic acid (18:1), α-linolenic acid, linoleic acid, dihomo-γ-linoleic acid (20:3), eicosapentaenoic acid
(20:5) and docosahexaenoic acid (22:5)) levels were increased in the newly diagnosed T2DM females
whom progressed from GDM while the rest of lipid metabolites decreased compared to controls. The
lactosylceramides (LCer), ceramides and SM which were found decreased in the newly diagnosed
T2DM females were LCer (16:0), LCer (24:1), Cer (16:0), Cer (20:0), Cer (22:0), Cer (24:1) and SM
(20:1) [101]. These findings of Khan et al. [102] are in contradiction to the previous cohort findings
(as described above) in respect to levels of ceramides and other sphingolipids. The reason for this
conflict may be due to the inclusion of obesity as a covariate in their statistical analysis while Khan
and his colleagues controlled the obesity covariates by pair-matching of BMI in the population. In
short, most of PL are considered validated and reliable future risk biomarkers of T2DM. The inclusion
and consideration of a positive relationship of short-chained-monounsaturated TG with T2DM also
improved the predicting-power of models and came up as unswerving biomarkers. LysoPC and
LysoPE were found in a reverse relationship with the occurrence of T2DM except in SNP-diabetes. TG,
LCFA, SM, ChoE, and Cer also increased in concentration and showed a direct correlation with the
onset of T2DM. In the case of PC, it is difficult to generalize the results for this highly diverse class of
PL. Most PC are also increased in the prediabetic state, however, depending on the nature and function
of individual PC metabolite, few PC compounds are also found in reciprocal relationship with the risk
of PC. The risk factor biomarkers of GDM are different than the prediabetes biomarkers.
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Acylcarnitines: acylcarnitines were also found to be potent early reporters of impaired glucose
tolerance or otherwise T2DM risk. They are usually generated during the esterification of fatty
acids (FA) as per requirement of transporting the FA into mitochondria. The disturbed mitochondrial
bioenergetics or mitochondrial stress leads to mitochondrial dysfunctioning which is another phenotype
of pre-diabetes leading to a build up of these FA and FA-derived metabolites resulting in incomplete
FA oxidation [103,104]. Based on these findings, it was proposed that incomplete oxidation of FA prior
to the IR may provide an opportunity to explore novel biomarkers of diabetes. Additionally, carnitines
are considered solely responsible for the transportation of LCFA across the inner membranes of
mitochondria for β-oxidation and incomplete oxidation of these carnitines produces an intermediated
carnitines oxidation called acylcarnitines [103]. Malonyl-CoA, a precursor of malonylcarnitine, plays a
significant role in the completion of β-oxidation of fatty acids by inhibiting the expression of carnitine
palmitoyltransferase I. The expression level of Malonyl-CoA was found to decrease in the obese
and diabetic subjects leading to incomplete β-oxidation of FA and generating acylcarnitines [105].
Furthermore, cellular lipotoxicity also happened due to excessive accumulations of these partially
oxidized FA in livers, muscles, adipocytes andpancreatic β-cells paving the way to IR and loss of
pancreatic β-cells function. This recognized pre-diabetic state is followed by the less disintegration of
LCFA and blunted oxidation of carbohydrates at a cellular level. This event is further accompanied by
the imbalance of accumulating LCFA and cellular oxidative capacity leading towards the pile up of
lipid-derived moieties (especially carnitines, ceramides, diacylglycerol) which attenuate the insulin
signaling by activating the protein kinase C enzymes, and inhibiting Vakt/PKB murine thymoma
viral oncogene homolog/protein kinase B respectively. The perturbation of LCFA catabolism in
mitochondria leads to the build up of SCFA which aids in the pro-inflammatory cascades and insulin
resistance [35,106].
Elevated plasma/serum circulating levels of several SC acylcarnitines (C2, C3, C4, C5, C6, C8),
medium chained acylcarnitines (C10, C10:1, C12, C12:1, C14, C14:1) and LC acylcarnitines (C16, C18,
C18:1, C20) have already been reported in the pre-diabetic, glucose intolerant and established diabetic
cases [55,104]. Many studies focused on identifying these incomplete oxidized LCFA products to
set up the signature biomarkers for IR or T2DM [35,106]. The plasma metabolic fingerprinting of
weight/age-matched diabetes/non-diabetic African-American women with/without uncoupling protein
3 (UCP3) (missense polymorphism, g/g or g/a), that reduced the oxidation of LCFA, revealed two
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acylcarnitines namely glutamate and 2-oxoglutarate (α-ketoglutarate) were found to be substantially
increased in diabetic women with a g/g allele. The already perturbed BCAA and cysteine catabolism
also contributed to the stressful anaplerotic process related to IR as isoleucine, leucine, valine and
cysteine are the precursors of succinyl-CoA and succinate. Concurrent with this concept, enrichment
of plasma valine occurred with the reduction of propionylcarnitine accompanying worsening of
blood glucose control and plasma accumulation of acetylcarnitines [35]. Adams and his team [106]
discretely found 42 acylcarnitines and free carnitine in overweight, obese diabetic and non-diabetic
subjects with or without UCP3 g/g or g/a polymorphism. Two carnitines were found in different
amounts with respect to genotype in g/g and g/a polymorphic subjects. In diabetic polymorphic
subjects, C12 carnitines were higher in g/g subjects compared to g/g diabetic patients. Non-diabetic
polymorphic patients showed more variation in butyrylcarnitine with 57% reduced content in g/a
participants. The concentrations of lactate carnitines were lowered in both polymorphic non-diabetic
and diabetic subjects. Irrespective of genotype factors, total carnitines:carnitine ratios rose up to
150–170% in diabetic patients. Acetylcarnitine was the most abundant carnitine moiety which also rose
to 157% in diabetic patients (Table 1). Among the medium-chain (MC) carnitines, the level of C6–C10
carnitines rose to 300% in T2DM patients accompanied by a 36% reduction in propionylcarnitine
concentration. The blood level of only one carnitine called propionylcarnitine was found in inverse
relation with the glucose level in blood [106]. A cross-sectional prospective cohort study with subjects
from Nutrition and Health of Aging Population in China (NHAPC) identified that individuals who
developed T2DM in the follow-up of 6 years showed higher baseline plasma concentrations of SC, MC
and LC acylcarnitines [107]. A strong correlation has also been found to exist between these (especially
LC) acylcarnitines and (baseline) fasting blood sugar, metabolic traits, HbA1c and insulin resistance.
Upon classification of acylcarnitines, only LC acylcarnitines have shown a strong association with the
future risk of T2DM. The per unit increase in SD of the odds ratios of these acylcarnitines showed a 2.48-
to 9.41-fold increase in risk ratio (RR) for the individuals in upper quartile. The results presented by
Sun et al. [107] only presented the correlation of baseline acylcarnitines and T2DM in Asian populations
so recently these findings were retested and confirmed by the another nested, case-controlled cohort
study of the PREDIMED (Mediterranean Diet in the Primary Pprevention of Cardiovascular Disease)
framework [108]. This study demonstrated that SC acylcarnitines (C2, C3, C4OH, C5, and C6) and MC
acylcarnitines (C16, C12) more firmly predict the future risk of T2DM compared to LC acylcarnitines
(C18, C18:1, and C20). Additionally, the correction of p and the adjustment of baseline plasma glucose
resulted in the strongest positive association of C5 acylcarnitines with the future risk of diabetes.
The authors also measured the per annum changes in the acylcarnitines level which were in line with
the baseline results. The per unit increase in the SD of C3, C4OH and C5 carnitines increased the risk
ratio of future T2DM up to 44% [108]. Another case control study was conducted on the American
population (sedentary lean, obese with glucose intolerance and obese with T2DM) targeting only 46
compounds of acylcarnitines. The authors noted an obvious increase of saturated and unsaturated
LC acylcarnitines, C14–OH– and C16–OH–CN, and plasma free acylcarnitines both in obese + T2DM
and obese + glucose intolerant subjects relative to sedentary lean non-diabetic people. In relation to
pre-diabetic and lean non-diabetic individuals, the T2DM people with obesity were found to have
increased plasma levels of SC and MC acylcarnitines [109]. The lean diabetic patients were found to
have significantly elevated plasma levels of C4– and C6–CN acylcarnitines whereas obese diabetic
subjects were found to have higher plasma levels of C4-dicarboxylcarnitine (C4 DC–CN). Regarding
gender, two notable exceptions were C3 and C5 acylcarnitines which were found to be higher only in
obese diabetic men compared to obese diabetic women [108]. Another two human clinical trials also
described the acylcarnitine pattern in obese and lean persons with/without diabetes suggesting short
chained acylcarnitines as a reliable biomarker of future risk of T2DM in both sexes [32,106]. But C3
acylcarnitines were increased in obese diabetic subjects compared to C3 acylcarnitines levels in obese
but yet non-diabetic subjects [32,106]. The untargeted metabolomics study on the plasma samples of
578 Swedish men recruited under the framework of the Uppsala Longitudinal Study of Adult Men
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(ULSAM) [60] detected four acylcarnitines raised in the pre-diabetic subjects and among these four
acylcarnitines, two MC acylcarnitines (C10, and C12 carnitines) have been found to be involved in
the early prediction and pathogenesis of insulin resistance [110]. The findings of another published
work found that MC acylcarnitines began to increase before the LC acylcarnitines, therefore, MC
acylcarnitines’ altered levels are more potent early signs of mitochondrial dysfunctions and disease
progression. Recently, Libert et al. [111] also explored the possible plasma acylcarnitines difference
in metabolic-well-but-lean, overall-metabolic-well-but-obese, metabolic-unwell-and-prediabetic
and diabetic-obese human subjects. The data of this study clearly mentioned the increased
plasma level of SC acylcarnitines and ratio of SC acylcarnitines: total acylcarnitines in
overall-metabolic-well-but-obese, metabolic-unwell-and-prediabetic and diabetic-obese human subjects
compared to metabolic-well-but-lean. Libert and his colleagues [111] found elevated levels of
3-OH-butyrylcarnitine and 3-hydroxybutyrate in metabolic-unwell-and-prediabetic and diabetic-obese
human subjects compared to metabolic-well-but-lean control subjects. A few previous studies also
mentioned the increased plasma level of malonylcarnitine or sum of 3-OHbutyrylcarnitine and
malonylcarnitine in prediabetic and diabetic subjects [55,107]. It is worth adding here that Zhang
and his colleagues also added contradictory results which showed that human subjects with NGT,
pre-diabetes and newly diagnosed T2DM could not be differentiated merely on the basis of short-chain
and medium-chain acylcarnitines [56]. The authors noted higher concentrations of LC carnitine esters
(i.e., carnitine C22, palmitoylcarnitine C16, carnitine C20, 3-OH-hexadecanoylcarnitine C16-OH and
carnitine C24) in the newly diagnosed pre-diabetes group and T2DM groups. The concentration
of free acylcarnitines was significantly higher in the pre-diabetic (25.33 mmol/L) and newly
diagnosed diabetic subjects (25.33 mmol/L) compared to subjects with normal glucose tolerance
(20.28 mmol/L) (Table 1). The correlation of serum acylcarnitines with prediabetic states such as
impaired glucose tolerance (IGT) and isolated impaired fasting glycaemia (IFG) were differentiated
depending on serum concentrations of acetylcarnitine. The serum concentrations of acetylcarnitine
(C2), tetradecenoylcarnitine (C14:1) and octadecenoylcarnitine (C18:1), were found to have a positive
correlation with the IGT whilst C2, hexanoylcarnitine (C6), octenoylcarnitine (C8:1), decenoylcarnitine
(C10:1), malonylcarnitine/hydroxybutyrylcarnitine (C3DC + C4OH), hydroxyhexadecanoylcarnitine
(C16OH) and tetradecenoylcarnitine (C14:1), were found in significantly higher levels in the T2DM
patients. The two groups IGT and IFG were distinguished by the serum levels of tetradecadienylcarnitine
(C14:2), tetradecenoylcarnitine (C14:1) and octadecenoylcarnitine (C18:1) [56]. The authors also
correlated body fat with the serum (free) carnitines levels and found that a significant positive
correlation exists between body fat and free carnitine and the acylcarnitines (C16:1, C8:1, C6, C5,
C4, C3, C2) but negatively with C14:2 and C18 acylcarnitines [55]. Previously, a metabolomics
approach was also used to reveal the correlation of body mass fat with various metabolites (especially
acylcarnitines) abundance between the healthy lean and healthy obese subjects who also underwent
the dietary (hypocaloric diet), bariatric surgery and physical exercise interventions. The targeted serum
metabolomics showed glutamine and the C18:1, C18:2, C14:1-OH, and C2 carnitines as varyingly
abundant in the serum of the two groups. C3 carnitines (with 6 isoforms) were found to be the most
powerful body fat mass related markers which were found to be up-regulated in obese subjects and
remained uninfluenced by the exercise intervention. However, the low carbohydrate diet intake
following bariatric surgery reduced the expression of C3 carnitines which bespeaks higher expression
of C3 in body fat mass. The physical activity resulted in an increase of carnitines in both the lean and
obese groups, however, this increase was found to be diminished after 24 h [57].
Urinary metabolomics using MS also revealed that diabetic and obese subjects excrete more urinary
LC acylcarnitines in comparison to healthy controls [104]. Van der Kloet et al. [99] also employed a
urinary metabolomics approach to differentiate progressive and non-progressive forms of albuminuria.
The diabetic patients with progressive forms of albuminuria were found to have higher urinary
metabolites from acidic/carboxylic acidic (i.e., benzoic acid, 5-hydroxymethyl-2-furancarboxylic acid,
galactonic acid, and hippuric acid), acyl-glycines (i.e., 2-phenylacetoxy-propionyl, glycine, salicyluric
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acid, and 3-methylcrotonylglycine), acylcarnitines, and tryptophan metabolism metabolite compared
to non-progressive forms of albuminuria. Dellow et al. [112] also added that persons with lose glycemic
control excrete more urinary acylcarnitines which might be the result of reduced renal absorption
or carnitines acylation. Tamamog˘ullari et al. [102] reaffirmed that serum levels of total and free
carnitines were higher in T2DM patients having no complications rather than diabetic patients with
diabetic retinopathy.
The role of acylcarnitines in progression from gestational diabetes mellitus (GDM) to T2DM
has also been recently studied [103,113]. These studies noted significantly higher plasma levels
of SC acylcarnitines in newly diagnosed GDM women. These works also emphasizes on MC
acylcarnitines due to their unlearned role in the pathogenesis of GDM to T2DM. These MC
acylcarnitines (i.e., octanoylcarnitine (C8-acylC), hexanoylcarnitine (C6-acylC), laurylcarnitine
(C12-acylC), decanoylcarnitine (C10-acylC)) were also observed in the newly diagnosed GDM patients
compared to NGT subjects [103,113]. Gall et al. [114] registered the decrease in MC acylcarnitines
especially decanoylcarnitine in the case of insulin resistance. The population-based KORA cohort
study also reported a decreased level of three metabolites namely glycine, acetylcarnitine, LPC (18:2)
in GDM women [4]. The transition of GDM to T2DM was also studied in a SWIFT sub-cohort study
which further added the increased level of C6 and C8 acylcarnitines in those GDM patients which
transit from GDM to T2DM in a follow-up of two years [115]. Anderson et al. [97] used the data-driven
approach (free of any hypothesis) and reported a decrease in the LC acylcarnitines (i.e., dodecanoyl-,
octanoyl-, decanoyl-, and tetradecanoyl-) in both pregnant women groups with previous GDM
history and those found in the upper quartiles of the glycemic index compared to the control group.
In short, acylcarnitines are not only reliable early reporting biomarkers of DM, but can also be used
to differentiate different states of metabolic syndrome such as pre-diabetic, IR, obese, SNP-diabetic,
GDM and IPD. Some of acylcarnitines such as glutamate, propionylcarnitine malonylcarnitine,
sum of 3-OH-butyrylcarnitine and malonylcarnitine, 2-oxoglutarate, C3, C5, C4–OH, C12, C14,
C14:1, C16, C18:1, C20 carnitines, butyrylcarnitine, 3-OH-hexadecanoylcarnitine, dodecanoylcarnitine,
octanoylcarnitine, decanoylcarnitine and tetradecanoyl carnitine can be readily currently employed to
diagnose subjects with IFG, T2DM, IR, GDM, IPD, and IGT.
Free fatty acids (FFA): two common origins of circulating FFA are de novo lipogenesis from
excessive carbohydrates and cleavage of TG in chylomicrons. The FFA metabolism dysregulation is
a key event in the emergence of insulin resistance and Randle et al. [116] proposed the preferential
oxidation of FFA over glucose as a major episode leading to metabolic syndrome. The significant
correlation of plasma concentration of FFA with dyslipidemia and T2DM was seen for the first time
and confirmed in the studies of Jones et al. [117] and Taylor et al. [118]. These studies reported
significant alterations in the plasma levels of LCFA between the diabetic and control groups. Later
on, some studies also suggested the involvement of altered plasma FFA levels in influencing insulin
sensitivity and impaired glucose metabolism. The saturated FA (SFA) including palmitic and stearic
acid were found in positive relation with glucose intolerance, impaired insulin sensitivity, impaired
insulin secretion and HbA1c. The unsaturated oleic acid was a biomarker of inadequate diabetes
control [119]. The lipidomics studies of erythrocytes membranes showed a greater palmitate content
(31.1 ± 2.4% in T2DM, 25.4 ± 3.1% in controls, p < 0.005) in isolated erythrocyte membranes with a
higher SFA/unsaturated FA ratio affecting the fluidity of cells [120]. Grapov and his colleagues [121]
investigated the relationship between NEFA and signaling lipids (oxylipins and endocannabinoids)
influencing the insulin signaling, inflammation and adipose function. The authors noted a 114%
increase in the circulating FFA at baseline which additionally positively correlated with the glucose
intolerance in diabetic patients. The net concentrations of SFA (14:0, 16:0, 18:0, 19:0, 20:0), MUFA
(16:1n7, 18:1n7, 18:1n9, 20:1n9), PUFA (18:2n6, 18:3n3, 22:4n6, and 22:5n3), and trans-FA (trans 16:1n7,
trans 18:2n6) were found to be elevated in T2DM patients. The linoleic acid andα-linolenic acid-derived
epoxides also increased by 47–127% and showed a positive correlation with SFA and MUFA in diabetic
patients. The arachidonate-derived 14,15- and 11,12-dihydroxyeicosatrieneoates were also increased by
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86% in diabetic patients. The OPLS-DA based predictive model also described a shift in the metabolic
profile. Four FFA i.e., 18:1n9, 18:0, docosahexaenoyl-ethanolamide (DoHex-EA) and 22:5n6 were
the main discriminating FFA between healthy and diabetic individuals. The 18:0 and 18:1n9, and
20:4n6 and 22:5n6 were the early reporters of diabetes related changes in the activity of stearoyl-CoA
desaturase and LCPUFA biosynthesis [121]. The Uppsala cross-sectional cohort study found higher
serum concentrations of SFA namely palmitic acid (16:0), myristic acid (14:0), and palmitoleic acid
(16:1w-7) and reduced serum concentration of omega3/omega6 fatty acid in individuals who develop
diabetes over the course of 10 years. The logistic regression based predicting model used in this study
identified oleic acid, palmitoleic acid, dihomo-7-linolenic acid and stearic acid as contributors towards
hyperglycemia and dyslipidemia [122]. The relationship of individual FFA with T2DM was further
elaborated in literature by Wang et al. [123]; Lapolla et al. [124] and Yang et al. [125]. The work of Wang
et al. [123] clearly elaborated that the percentage of SFA and MUFA was higher at the baseline in those
people who developed T2DM over the course of 9 years in the Atherosclerosis Risk in Communities
(ARIC) Study. With respect to individual FA, the findings of Wang et al. [123] are in complete
agreement with the previous findings of Vessby et al. [122]. Among the cholestrolemic esterified FA,
(16:0), palmitoleic (16:1n-7), and dihomo-α-linolenic (20:3n-6) were found in positive association with
incidence of T2DM, whereas in PL, the C16:0 and C18:0 were in positive relationship with the T2DM
occurrence [123]. Yang et al. [125] used the PCA non-linear mapping (PCA–NLM) approach and also
found FFA i.e., 18:1n9, 12:0, 18:3n3, 18:1n7, 20:5n3, 20:2, 22:5, and 22:6 as early discriminators between
potential T2DM patients and healthy controls. Conflicting results have also been reported in the
literature stating only even-chained SFA (14:0 to 18:0) in a constructive association with development
of diabetes whereas LC SFAs (20:0 to 24:0) and odd chain SFA showed opposite trends [126]. The most
comprehensive work in this respect and to also quantitatively relate the FFA with T2DM was published
by Tan et al. [127] who used the competitive adaptive reweighted sampling (CARS) method with
PLS-DA to seek the most probable biomarkers of diabetes. This study found three FFA i.e., α-linolenic
acid (18:3n-3), oleic acid (18:1n-9), and eicosapentaenoic acid (20:5n-3) as the predictive biomarkers
of future T2DM risk. The elongation of FFA was also correlated with the insulin resistance and
LCFA-elongase (Elov16)-led conversion of palmitate to stearate was found to play a major role in the
emergence of pathogenesis of T2DM [128]. The prospective cohort study on healthy/diabetic Uyghur
and Kazak Chinese distinguished T2DM individuals from healthy controls were having high 22:6 and
20:4n6, and lower 22:0, 14:1, 18:3n6, and 20:3n6 fatty acids plasma concentrations from baseline [129].
The FFA are also believed to attach with peroxisome proliferator-activated receptors (PPAR) and
modulate the transcription factors contributing towards metabolic syndrome. Attaching with the PPAR
prompted the proinflammatory responses and impaired endothelial function in non-pregnant healthy
subjects [130]. Pankow et al. [131] stated that the correlation of high fasting FFA with the incident
of T2DM is independent of sex, waist/thigh ratio, percent body fat, fasting TG concentration, and
insulin-mediated glucose uptake. A more recent cohort study reported 3–4 times higher serum FFA
levels amongst the newly diagnosed and long time-monitored diabetic patients whereas a moderate
correlation was found in the pre-diabetic patients. The authors further recommend the measurement
of serum FFA concentration in combination with existing diabetic diagonostic tools to improve the
diagnostic accuracy. This study ranked the earlier diagnostic accuracy from the newly diagnosed
diabetic patients to those monitored for a long time [132]. Yi et al. [133] demonstrated both esterified
and non-esterified FA to screen the DM patients from healthy ones. The esterified FA were mostly
storage lipids (cholesterol, TG, PL esters) which are also considered the precursors of non-esterified
fatty acid. Taking into consideration other variables (body weight, age and sex), the authors identified
nine potential biomarkers (total NEFAs, 24:0, 20:3, 14:0, 18:1n7, 16:1n9, 16:0, 18:1n9, 18:0) to separate
the T2DM and healthy individuals. Among these FFA, the coefficients of 16:0, 18:1n9, and 18:0 were
quite high in T2DM patients compared to controls [133]. The MCFA, beta-hydroxyisovalerate and
arachidonates was lowered in T2DM while LCFA including essential FA linolenate and linolate was
elevated in comparison to controls. This study demonstrated decreased PC (hence HDL and total
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cholesterol) and increased PE (TG) contents in diabetic patients [65]. In line with these results, Gall
et al. [114] also found lower levels of multiples glycerophosphocholine species which are highly
associated with insulin resistance.
Furthermore, the existing evidence in literature on this topic is still inconclusive and not many
studies unequivocally consider the dietary intake of carbohydrates, fats and alcohol influencing de
novo lipogenesis of FA. Addressing these issues, some nutritional interventional cohort studies focused
on these shortcomings and started to correlate the dietary fat intake with the elevated level of FFA
and incidence of diabetes. In a large US prospective Health Professionals Follow-Up Study (HPFS),
plasma metabolomics of the participants with the validated self-reported HFD consumptions found
31–52% less risk of incidence of diabetes with the increased plasma concentrations of marker dairy
fat FA namely 15:0, 17:0, and trans-16:1n-7 [134]. The correlation of dairy fat consumption derived
trans-palmitoleate concentrations with dyslipidemic biomarker LDL-C was also investigated in a
multi-ethnic cohort study “Multi-Ethnic Study of Atherosclerosis”. The consumption of dairy fat was
found to be positively associated with an increased plasma concentration of trans-palmitoleate and this
trans-palmitoleate concentration in turn positively correlated with LDL-C and negatively with fasting
insulin levels and TG [135]. The increased FFA concentration interferes with the insulin signaling
causing peripheral insulin resistance or reduces the accessibility of insulin to skeletal muscles ultimately
reducing the glucose transport towards muscles. This lipotoxcity also harms the β-pancreatic cells
resulting in the impairment of insulin secretion.
Previously, many studies have also established the relationship of FFA level with the GDM
in pregnant women. The experimentally created acute elevation in the FFA caused an increase in
insulin resistance in both non-pregnant/pregnant women with/without GDM/T2DM. Elevated blood
levels of FFA also resulted in the up to 47% diminution of insulin-stimulated glucose uptake and
glycogen synthesis [136]. More recently, the relationship of maternal individual FFA level with GDM
and inflammatory response has also been studied [137]. This study indicated a positive relationship
of palmitic, stearic, dihomo-γ-linolenic (DGLA), and arachidonic acids with the C-peptide level,
cytokines/adipokines, and GDM. In addition to GDM, the other most undiagnosed form of prediabetes
is isolated post-challenge diabetes (IPD). The interpretation of T2DM based only on fasting blood
sugar fails due to the fact that IPD is often overlooked and misdiagnosed due to its normal fasting
glucose levels during the screening process of T2DM, and many authors devised some metabolomics
strategies to cover up this gap [138,139]. These studies focused on the FFA profile of such patients
and cited concentrations of most of FFA were substantial enough to discriminate between the healthy
controls, T2DM and IPD. The concentrations of FFA were lower in healthy controls than T2DM and IPD.
Moreover, the three FFA (i.e., 18:1, 18:2 and 18:3) can be used as validated biomarkers for diagnosing
the T2DM/IPD subjects from the healthy ones. However, to use 18:2 for screening purposes of T2DM,
it is necessary to determine the concentrations of 16:0 and 18:0 too, to differentiate the healthy patients
from T2DM. 16:0 can be used to distinguish T2DM and IPD individuals [138,139]. In another study, the
authors stated the 15 most significantly varying metabolites among healthy, T2DM, and IPD individuals.
The concentration of oleic acid, cholesteryl-β-d-glucoside, linoleic acid, 1,2-distearoyl phosphatidyl
serine increased in the T2DM and IPD groups whereas other metabolites, such as lysoPE, DHEA-S,
lysoPC, and 5-hydroxykynurenine were considerably lower in both of these groups as compared to
healthy individuals. The concentration of three metabolites namely DHEA-S, linoleic acid and oleic
acid were found to discriminate IPD and T2DM patients [28].
5. Biomarkers of Disturbed Microbiome and Microbiome-Related Metabolites
Organic acids (OA) are produced by intestinal microfloral action on sugars and proteins in addition
to glycolysis, lipolysis, gluconeogenesis and AA metabolism. Therefore, it is quite important to also
discuss the OA as early biomarkers of diabetes.
OA: human OA metabolites are the compounds with carbon chain length varying from C2 to C6
and majorly produced by the fermentation of carbohydrates and AA. Straight-chain OA are usually
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produced by the colon-inhibited-microfloral fermentation of starchy and fibrous dietary material
whereas branched-chain-OA (BCOA) are produced by bacterial metabolism of AA. The other ways
of OA production are the various metabolic pathways i.e., glycolysis, lipolysis, gluconeogenesis and
Krebs cycle. Any variations in intestinal microfloras’ compositions usually bring about the changes in
the concentrations of plasma/urine/serum/fecal OA which made these short-chain entities tremendous
biomarkers of various metabolic syndromes [140]. It is estimated that human beings fulfill their 10%
daily energy requirements from these OA [141] and crucial involvement of OA in metabolic procedures
(e.g., mitochondrial energy production, nutrient deficiencies, free radical overload, intestinal dysbiosis,
and so on) importantly relate them to various biological processes. These gut microflora-produced
OA are usually absorbed in the colon to maintain the necessary redox balance and in exchange of
bicarbonates. OA are also transported from the lumen to different organs where these compounds
act as a substrate and are involved in energy homeostasis signaling including lipids, glucose, and
cholesterol metabolism in tissues [142]. There is accumulated evidence in literature proposing the
(short-chained)-OA the biomarker for DM and other health conditions [143]. Being the central metabolic
regime of energy molecules, Krebs cycle is the first to be perturbed in the case of diabetes-induced
enzymatic variation which after all can cause an insufficient recycling of OA. Therefore, many studies
also declared OA as a marker of DM, central nervous system diseases, organic acidurias and other
metabolic disorders etc. [143–146].
Three OA namely acetic acid, propionic acid and butyrate are known for their health-promoting
activities. The plasma levels of these OA were found to decrease in persons prone to IR, IGT, IFG IPD,
obesity and T2DM [147]. Butyrate is a more important reporter of early obesity induced metabolic
syndrome in this regard as its decreased concentration was found in obese and pre-diabetic individuals.
On the other hand, the increased concentration of butyrate is a symbol of well-being as it suppresses
the insulin resistance and weight gain. The increased production of butyrate, by modulation of
intestinal micoflora diversity, led to less increased IR and weight gain in HFD-diabetic mice [148].
The inoculation of butyrate producing gut microflora in germ-free-lean mice with metabolic syndrome
also showed improved insulin sensitivity [149]. Recently, metagenomic data also supported the fact
of a substantial decrease in the butyrate producing gut microbiota in obese mice [150]. The butyrate
supplementation in HFD also reduced weight gain and improved insulin sensitivity in obese C57BL/6
mice [142]. Beside butyrate, propionic and acetic acids, patients prone to metabolic syndrome or
diabetes were found to have up to a 14-fold higher OA (adipic acid, suberic acid, 3-hydroxyisovaleric
acid, 2-hydroxybutyric acid, aceto-acidic acid, 5-hydroxyhexanoic acid, lactic acid, 3-hydroxybutyric
acid, fumaric acid, 5-hydroxic hexanoic acid, 2, 3-dideoxypentonic acid) content in their urine due
to the phenomenon of generous liberation of FFA from adipose tissue followed by β-oxidation of
FA [143,144,146]. Interestingly, an increased concentration of most of these OA suppressed the insulin
signaling by activating the free fatty acid receptor 2 (FFAR2) while simultaneously promoting the
glucose/lipids metabolism in tissues and preventing the lipid accumulation in adipocyte tissues (i.e.,
weight loss) [149]. Moreover, immune and adipose tissues have two G-protein-coupled receptors
(GPCR) (i.e., GPCR 41 and GPCR 43) for (short chained)-OA which are further linked to G-protein
for further downstream targeting. Among the major four classes of G-proteins (i.e., Gi/o, Gs, G12/13,
and Gq/11), each class is specified for certain GPCRs which proposed the involvement of SCOA
in modulating the response of adipose/immunity tissues [151]. The existence of OA receptors on
the surface of immune and adipose tissues suggested the modulatory roles of these metabolites in
biological processes. The GPCR41/GPCR43 knockout mice studies showed a huge inflammatory
response in various metabolic conditions due to GPCR41/GPCR43-/-immune/adipose cells [152] Whilst
the supplementation of butyrate or propionate decreased the mRNA expression levels of inflammatory
cytokines GPCR41/GPCR43 knockout mice. The acetate, propionate and butyrate reduced the TNF-α,
cytokine and chemokine release from the monocytes and neutrophils while promoting prostaglandin
E2 production. These studies concluded that SCOA has a modulatory role in the inflammatory status
of obese tissues and thus in IR [153,154].
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Han and his team [144] also stated a 0.1–66% increase in plasma contents of 10 OA
(acetate, propionate, isobutyrate, 2-methylbutyrate, 3-methylevalerate, isovalerate, valerate, caporate,
isocaporate), including three C5 and C6 isomers and two C4 isomers, in T2DM diagnosed patients. The
gas chromatography–mass spectrometry (GC-MS)-based metabolomics analysis of serum OA unveiled
a higher concentration of glucose intermediates i.e., 3-OH-butyric, lactic acid, adipic, succinic, citric,
palmitic, and phenyl acetic acids) in diabetic subjects. The higher excretions of these OA were also cited
as an indicator of underlying undiagnosed conditions belonging to metabolic syndrome. The higher
excretion of adipic acid, 3-OH-butyric acid and suberic acid were synonymous to the occurrence of
ketogenesis and the formation of C6–C8 fatty acids due to beta-oxidation in pre-diabetic patients [155].
The pre-diabetic patients were found to excrete higher levels of 2-OH-butyric, hydroxy-isobutyric
acid and 3-OH-butyric acid and low levels of sebacic acid, whereas, obese people only excrete
higher amount of suberic acid relative to non-obese and non-diabetic subjects. Higher excretion of
hydroxy-isobutyric acid in diabetic patients also indicated a higher fat metabolism resulting in higher
serum levels of C4 moieties [155]. Chou et al. [156] carried out the serum metabolomics using the
GC-MS platform to discriminate normal, diabetic and IPD patients. This study stated sixteen early
biomarkers of diabetes clearly distinguished the individuals at T2DM risk from healthy controls and
nine metabolites successfully differentiating the people at risk of diabetes or IPD. Two OA biomarkers
namely pyroglutamic acid and α-hydroxybutyrate (α-HB) clearly distinguished the IPD and non-IPD
(healthy and T2DM), and healthy vs. IPD individuals, respectively [146,157,158]. β-HB, ethylmalonic
acid, and α-HB proved to be signature biomarkers to distinguish between healthy controls and
T2DM patients. Moreover, lactate and ethylmalonic acid categorized individuals at IPD and T2DM
risk [156,159]. The levels of β-HB and α-HB increased in ascending order from healthy controls to IPD
and diabetic patients. The α-HB has also been proposed as a biomarker of the IR and IGT [88]. Most of
the detected OA metabolites were identified as TCA cycle intermediates which level was found to
fluctuate mostly in diabetes, CKD and CHD. Some studies also cited altered levels of these metabolites
in the cardiac and nerve tissues of diabetic persons [160]. Citrate and pyruvate were already declared
in perturbed amounts in the urine of diabetic patients. The TCA intermediate succinate was found to
be increased in the plasma of patients who developed T2DM [161]. The work of Yuan et al. [146] also
defined SCOA (e.g., 4-aminobenzoic acid and oxyl acetic acid) as a predicting biomarker for T2DM
risk. Chou et al. [156] also stated pyroglutamic acid as a promising biomarker for distinguishing IPD
and healthy non-IPD patients whereas pyroglutamic acid was found decreased in diabetic patients [88].
Sato et al. [162] also observed higher concentrations of isovaleric acids in T2DM patients in a blind,
randomized and case-control cohort study. Many studies have documented the higher excretion of
other OA (especially uric acid) in diabetic patients compared to healthy controls [140,163,164]. These
published results also claimed a higher urine OA being the main causative of uric acid stones and
nephrolithiasis in diabetic subjects. The uric acid and sodium retention was also observed in insulin
resistance and HOMA-IR model. It also proved a strong relation between high uric acid and the low
urine pH and insulin resistance [165]. A low urinary pH can also be a validated marker of future insulin
resistance as Abate et al. [166] selected his subjects merely on the basis of the presence of uric acid
kidney stones. But later these subjects unveiled less insulin sensitivity and lower urinary pH. Therefore,
the patients with low urinary pH are at a stage of increased risk of T2DM development. These studies
successfully proposed and defended the so-called obvious correlation between low urinary pH and
T2DM/obesity, however, these studies also came up with some major limitations such as ignoring the
major dietary, environmental and lifestyle factors in these cross-sectional cohort studies. These factors
were partially addressed by Maalouf et al. [167] who provided the fixed metabolic diet to the diabetic
patients for the whole study duration. The T2DM patients showed higher net acid excretion (NAE)
(NH4+ + TA) value which symbolized the higher net acid production in diabetic patients. However,
this data not only lacks the focus of mechanisms responsible for higher acid production in diabetes
but also states urinary anionic measurements being non-significantly different between diabetic and
non-diabetic subjects which helped out to formulate the idea of GI alkali loss in diabetic individuals.
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The accumulation of pancreatic fats which affects the bicarbonates secretion and exocrine activities may
result in GI alkali loss in T2DM. Alternatively, some other studies proposed greater intestinal micoflora
fermentation due to a delayed transient time in the colon in diabetic patients [168]. A low NH4+/NAE
ratio was also noticed in diabetic patients in some studies [169] with higher TA values in diabetic
patients. The impaired NH4+ secretion might be due to increased FA supply to renal tubules resulting
in compromised NH4+ excretion [167]. The work of Sato et al. [162] also published amazing data
about the effects of the administration of different diets and the consequent effects on organic acids in
diabetic and non-diabetic patients. The diets rich in saturated fatty acid/total fat negatively interlinked
with the organic acid concentration in both groups. Carbohydrates exhibited a positive association
with all fecal/plasma organic acids of diabetic patients. A further negative linkage was found between
the duration of diabetes and two organic acids named acetic acid and propionic acid. Isovaleric acid
was the organic acid least influenced by the dietary habits of diabetic subjects [162]. Conclusively,
it is also possible to distinguish the normal, pre-diabetic, IPD, obese and T2DM individuals based on
the targeted serum/plasma/urine metabolomics focusing OA as early biomarkers of diabetes and or
various stages of diabetes.
Human gut microbiota signature biomarkers: the microbial lives of the whole gastro-intestinal
tract are collectively known as gut microflora or gut microbiota. The total number of gastro-intestinal
microbiota exceeds 100 trillion which is 3-fold more than the total number of human body cells, which
is why the gut environment is considered as a whole functional organ [170]. The five important and
predominant phyla of gut microbiome are Bacteroidetes, Actinobacteria, Proteobacteria, Firmicutes and
Verrucomicrobia. The composition of these phyla keeps changing throughout the gastro-intestinal
tract depending on various confounding factors such as individual lifestyle, dietary habits, health
and physiological factors determining which phenotype would be developed. Regardless of this
confounding drawback, gut microbial studies identified some gut microbial signatures as early
biomarkers for metabolic syndromes. Moreover, the gut microflora controls many metabolic reactions
by the production of many beneficial secondary metabolites (e.g., choline, phenols, bile acids, and
SCFAs etc.) involved in the various metabolic signaling pathways. Recent findings have shown
that gut microbiota is not only involved in maintaining optimal human health but it is also culpably
involved in the pathogenesis of metabolic diseases [150,171–173].
Recent studies have focused on unveiling the effect of changed dietary habits on the composition
and ecosystem of gut microflora. The consumption of fiber-deficient diets resulted in a lesser extent
of fermentation in gut and hence less production of systematic anti-inflammatory short-chain fatty
acids (SCFA). These SCFA are important for the synthesis and production of immunoglobulin A and
immune-supportive cytokines and failure to produce these health-supporting SCFA results in dysbiosis
which is in turn implicated in the increased incidence of diabetes and inflammatory diseases [174].
There have also been reports that the population of health-promoting SCFA-producing gut-bacteria
found to have decreased in individuals at risk of developing diabetes [175]. SCFA also promotes
the production of glucgone-like-peptide 1 (GLP1) and coheres with G-protein-coupled receptors.
The production of GLP1 impedes hepatic gluconeogenesis and glucagon secretion; promotes insulin
sensitivity and satiety and hence encourages weight loss. SCOA are another class of secondary
metabolites generally produced by the gut microflora. It has been noted that butyrate producing
gut-bacteria became less abundant followed by an increase in the population of Lactobacillus spp. and
Betaproteobacteria in obesity and T2DM compared to non-obese control healthy subjects [150,168,171].
The gut microflora population also becomes deficient in the Firmicutes and Clostridia in future T2DM
patients as noted by Laresn et al. [168]. The lowering of Clostridium in diabetic patients worsens the
glucose metabolism since this species is primarily involved in the conversion of primary bile acid into
secondary bile acid entities (i.e., cholic and chenodeoxycholic acids) in the large intestine [176,177].
The secondary bile acid entities actually activate the farnesoid X receptor (FXR) and G-protein-coupled
receptor 1. The activation of G-protein-coupled receptor 1 ensures the release of GLP-1 which is
important for proper pancreatic and hepatic functioning. FXR also controls the glucose metabolism
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and weight loss maintenance by down-regulating the expression of 6-biphosphatase-1, fructose-1,
glucose-6-phosphatase and gluconeogenic phosphoenolpyruvate carboxykinase [177,178]. So a lowered
population of gut Clostridium is another signal of obesity and perturbed glucose metabolism in glucose
intolerant persons. Firmicutes (Gram-positive) and Bacteroidetes (Gram-negative) bacteria comprised
almost 90% of gut microflora and some studies proclaimed the ratio of Firmicutes-to-Bacteroidetes as a
predictor of dietary habits and hence metabolic disorders linked to these dietary life styles. The obese
mice model studies registered a high Bacteroidetes-to-Firmicutes ratio with an increased proportion of
Bacteroidetes [179]. A positive correlation was also noted between the blood glucose level and the ratios
of Clostridium coccoides/Eubacterium rectale, Bacteroides/Prevotella, and Bacteroidetes/Firmicutes groups.
So the lowering of SCFA, SCOA and butyrate producing bacteria, Firmicutes, Clostridia population are
the early biomarkers of T2DM in glucose intolerant patients. Additionally, an increased population of
Gram-negative Bacteroidetes and Proteobacteria hinted their role in the pathogenesis onset of T2DM
via an endotoxin-led-inflammatory response as lipopolysaccharides and endotoxins were found in
higher concentration in their cell membranes [168]. Similarly, the transplantation of fecal microflora
from healthy and lean individuals containing the specific gut bacteria into diabetic persons ameliorated
the insulin sensitivity in the recipients. This transplantation improved the population of SCFA and
SCOA producing strains of bacteria in the insulin-resistant persons [180].
In recent years, human gut microbiome data has been used in conjunction with the metabolome
data to comprehensively assess the nutritional and metabolic health status of human beings. Qin et
al. [150] did a metagenomic study of gut microflora exploring the metagenome association with T2DM
in 345 diabetic + non-diabetic subjects. This metagenome-wide-study showed the enrichment of genes
with opportunistic pathogens such as Clostridium hathewayi, Bacteroides caccae, Clostridium symbiosum,
Clostridium ramosum, E. coli, Eggerthella lenta in T2DM individuals whilst SCFA, SCOA-producing
bacteria, including SS3/4, Clostridiales sp., Faecalibacterium prausnitzii, E. rectale, Roseburia inulinivorans,
and Roseburia intestinalis were found to be enriched in non-diabetic persons. Le Chatelier et al. [181]
documented that low bacterial richness/low bacterial gene count favors obesity, insulin resistance and
low-grade inflammation and fatty liver. The authors further added that based on the metagenomic
analysis of 46 genera of low bacterial gene count and high bacterial gene count, one can distinguish the
persons who are more prone to obesity/T2DM compared to those whom are less. Bacterial species such
as Ruminococcus and Bacteroides species which were more dominant in the low bacterial gene count
could be early predictors of metabolic disorders such obesity and T2DM whereas dominant species
(Bifidobacterium, Faecalibacterium prausnitzii, Alistipes, Akkermansia and Lactobacillus) of high bacterial gene
count are mostly associated with resistance to T2DM. This study supported the idea of a lack of SCFA
and SCOA producing bacteria, mucus degrading bacteria and sulfate reducing species (Desulfovibrio) in
the low bacterial gene count group [181]. Conflicting data were also registered by the European cohort
study describing the upregulated abundances of only A. muciniphila in individuals with less severe
metabolic syndrome, however, this upregulation in the abundance of A. muciniphila was concurrent
with an increased microbial diversity exhibiting the population-dependent relationship of A. muciniphila
and T2DM [171]. However, all three of the aforementioned cohort studies unanimously declared the
Lactobacillus species, Clostridiales and SCFA/SCOA-producing bacteria as main early discriminants
among healthy, glucose intolerant and diabetic human subjects [150,171,181]. The supplementation of
A. muciniphila in high-fat diet-induced obese mice also increased high-glucose-tolerance and lowered
inflammation by lessening the lipopolysaccharides and lipid oxidation [182]. The skewing of gut
microbial population, during the early, glucose intolerant and undiagnosed stages of diabetes, affects
the cell-to-cell integrity in the gut lining resulting in a leaky gut with increased permeability leading to
perturbed immune response and intestinal inflammation. All these variables attributed to influence the
T-cell mediated autoimmunity and related autoimmune disorders including diabetes [183,184]. Zhang
et al. [185] also performed the metagenomic study using the 16S RNA and short-gun sequencing method
to find the gut microflora signature markers among the healthy, pre-diabetic, and newly diagnosed
T2DM patients. The healthy controls were rich in Haemophilus parainfluenzae T3T1 and F. prausnitzii but
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less abundant in A. muciniphila and Clostridiales spp. SS3/4. The butyrate producing Roseburia intestinalis
and Faecalibacterium prausnitzii were found to be deficient in T2DM subjects with the abundance
of Streptococcus mutans, Lactobacillus gasseri and certain Clostridiales. A fall in the populations of
anti-inflammatory strains of Faecalibacterium prausnitzii and Roseburia (butyrate-producing Clostridialis)
were seen as an early sign of T2DM compared to healthy controls whereas enrichment of Akkermansia
muciniphila strains come along with signs of improved metabolic control in the obese mice [186].
The composition of gut microflora cannot always be synonymous to a function and that is why,
recently, some studies extended their investigation by correlating the gut microbiota composition
with their gut-microbe-derived metabolomics. These studies found increased BCAA levels in the
glucose intolerant patients prone to T2DM and this increased production of BCAA was correlated with
the increased prevalence of two bacterial strains i.e., P. copri and B. vulgatus [187]. Moreover, diet is
considered a key player in shaping the relationship of gut microbiota composition and metabolism
with the risk factors of T2DM, so many studies have devoted their objective on the effect of specific
diet consumption and their consequent effects on gut microbial communities and their metabolites.
The effect of macronutrient constituents of diet has been particularly discussed in the literature.
The prevalent intake of animal protein diets increased the T2DM related gut microbial signatures (i.e.,
Bacteroides and Clostridia) with the decrease of SCFA- and SCOA-producing bacteria e.g., Bifidobacterium
adolescentis. The comparison of plant-based-protein rich diets and animal-origin-protein rich diets was
also studied in detail which pointed to the dominance of Bacteroides, Alistipes and Bilophila (bile-tolerant
anaerobes) in the latter group of diet recipients [188]. The consumption of a high protein and low
carbohydrate diet also diminished the population of SCOA producing bacteria such as Roseburia
and Eubacterium rectale [189]. The consumption of a high-fat diet also caused an increased in the
population of Clostridia and Bacteroides whereas the intake of low-fat diet resulted in the abundance
of SCOA-producing bacteria. The consumption of saturated fat-rich-diet encouraged the setup of
Faecalibacterium prausnitzii and monounsaturated fat-rich-diet intake reduced the total gut bacterial
load [190]. Fish oil-fed mice harbored an elevated population of SCOA (especially butyrate and lactic
acid) producing bacteria i.e., Lactobacillus, Streptococcus, Verrucomicrobia, Bifidobacterium and Adlercreutzia
whilst lard-feeding showed an increased population of Bilophila and Bacteroides [191]. The consumption
of sugars (fructose, sucrose, glucose) increased the ratio of Bifidobacteria:Bacteroides. The addition
of lactose with other sugars replicated the same results but with lower population of Clostridia
species [192]. The consumption of artificial sweeteners produced inverted results with an elevated
community of Bacteroides [193]. The intake of non-digestible carbohydrate-rich diet (fiber/probiotic)
stimulated the community growth of beneficial anti-obesity fermentative commensal microbiota i.e.,
Bifidobacteria and Lactobacilli [194] whereas, on the other hand, prebiotics reduced the signature gut
microbial biomarkers of obesity and T2DM, i.e., Clostridium and Enterococcus [195]. The intake of
probiotics and prebiotics was found to decrease the risk factors and signature biomarkers of T2DM by
stimulating a decrease in blood glucose levels. The supplementation of probiotic strains (Escherichia coli
Nissle 1917, Lactobacillus plantarum 2142, Lactobacillus rhamnosus GG) or the supernatant of their spent
cultures or their metabolites increased the blood concentration of insulin, insulin sensitivity, improved
glucose tolerance and relieved the oxidative stress and oxidative stress-related proinflammatory
cytokines [196–198]. The administration of probiotics/prebiotics in addition with diet in different
mouse models (KK-Ay, NOD, and alloxan-induced-diabetic mice) witnessed the fading of signature
T2DM biomarkers i.e., lowered HbA1c, FFA, LDL-H, TG, FBG, and HOMA-IR with subsequent increase
in the Bifidobacterium and butyrate producing gut microbes [199]. The supplementation of diet with
polyphenols of varying origins increased the community size of Prevotella, Bifidobacterium, Bacteroides,
Bacteroides uniformis, Enterococcus, Blautia coccoides-E. rectale and Eggerthella lenta groups [200,201].
In summary, diminishing intestinal bacterial richness is the first biomarker of undiagnosed metabolic
syndrome. Considering the dietary, lifestyle and physical activity covariates, the persistent gut
prevalence of certain (pathogenic) microflora (i.e., Bacteriodetes, Clostridium coccoides, Proteobacteria,
Clostridiales, Lactobacillus spp., Betaproteobacteria, Streptococcus mutans, P. copri, B. vulgatus, Lactobacillus
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gasseri, Ruminococcus spp. E. coli, Eggerthella lenta) are also early risk predictors for metabolic syndrome
and pre-diabetic conditions. Likewise, a decrease in the intestinal population of SCFA and beneficial
SCOA are also reporters of a future risk of metabolic syndrome and diabetes.
6. Conclusions
The metabolic syndrome and diabetes mellitus are becoming more prevalent in both developed
and developing countries. The onset of diabetes can be deferred or even prevented if intervention is
accurate at early stages. The existing diagnostic clinical tools are not considered sufficient for early
prediction of these conditions. However, several perturbed metabolic biomarkers have been proposed
for early prediction of metabolic syndrome. These predictive and risk-factoring metabolic biomarkers
have been discovered using high-throughput technologies used in many cohort and predictive
modeling (metabolomics) studies. Reported metabolic biomarkers mainly belong to AA, BCAA,
SCOA, acylcarnitines, phopsholipids and FFA. These metabolites are considered the intermediate
metabolites of carbohydrates, lipids and amino acid-altered metabolism which ultimately distorted the
gluconeogenesis, glycolysis, lipolysis, the tricarboxylic acid cycle and proteolysis pathways. These
disturbed biomarkers showed significant correlations with elevated blood/plasma/serum glucose level,
fasting plasma glucose, insulin resistance, glucose intolerance, HOMA-IR, OGTT and obesity. Moreover,
most of these early diabetic biomarkers have been validated and are being used in newly established
phenome centers for the purpose of population-based screening. Gut microbes have also been found to
be influenced by (the early stages of) T1DM, T2DM and obesity. With some exceptions, the abundance
of Firmicutes, Actinobacteria, SCOA-producing-bacteria, Bifidobacteriaceae (Actinobacteria) and
Clostridium phyla was found to be lower in metabolic syndrome, obese and diabetic persons whereas
the population of Bacteroidetes, Lactobacillus spp., Rikenellaceae, Proteobacteria, A. muciniphila and
Desulfovibrio spp. was found to be richer in metabolic syndrome, obese, and diabetic individuals
compared to healthy subjects.
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